Meta-Analysis

Association of miR-196a2 rs11614913 and miR-499 rs3746444 polymorphisms with cancer risk: a meta-analysis

Wanjun Yan¹, Xiaoyan Gao¹ and Shuqun Zhang¹

¹Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China

Correspondence to: Shuqun Zhang, email: zhangshuqun1971@aliyun.com

Keywords: *miRNA, single nucleotide polymorphism, cancer susceptibility, meta-analysis*

Received: March 08, 2017 Accepted: August 29, 2017 Published: November 20, 2017

Copyright: Yan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Background: MicroRNAs (miRNAs) are small non-coding RNA molecules, which participate in diverse biological processes and may regulate tumor suppressor genes or oncogenes. Rs11614913 in miR-196a2 and rs3746444 in miR-499 are shown to associate with increased/decreased cancer risk. This meta-analysis was performed to systematically assess the overall association.

Materials and Methods: We searched Pubmed, Web of Knowledge, EMBASE, Chinese National Knowledge Infrastructure (CNKI) databases until December 2016 to identify eligible studies. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the strength of the associations.

Results: We assessed published studies of the association between these microRNA polymorphisms and cancer risk from 56 studies with 21958/26436 cases/ controls for miR-196a2 and from 37 studies with 13759/17946 cases/controls for miR-499. The results demonstrated that miR-196a2 rs11614913 was significantly associated with a decreased cancer risk, in particular with a decreased risk for colorectal cancer and gastric cancer, or for Asian population subgroup. In addition, miR-499 rs3746444 polymorphism was observed as a risk factor for cancers, in particular, for breast cancer, or for in the Asian population.

Conclusions: Our meta-analysis suggests that the rs11614913 most likely contributes to decreased susceptibility to cancer, especially in Asians and colorectal cancer and gastric cancer, and that the rs3746444 may increase risk for cancer. Furthermore, more well-designed studies with large sample size are still necessary to further elucidate the association between polymorphisms and different kinds of cancers risk.

INTRODUCTION

Cancer is reportedly one of the major causes of death among human worldwide [1]. According to GLOBOCAN 2012 report, there were 14.1 million new cases and 8.2 million deaths in 2012 [2]. Recently reported, as a very complex genetic disease, the mechanism of cancer has not been completely elucidated. Moreover, studies have suggested that cancer development results from geneenvironment interactions [3].

MicroRNAs (miRNAs) are a class of endogenous small single-stranded, long non-coding RNA molecules, which play critical roles in a extensive range of biologic and pathologic processes, especially in carcinogenesis [4–5]. Accumulating studies indicates that a single miRNA cantarget 200 genes, and approximately 20% of human genes are regulated by the mature miRNA molecules [6]. More than half of miRNAs genes are located in cancerrelated genomic regions, indicating that these miRNAs may play a more important key role in the etiology, tumorigenesis, development and prognosis of human cancers than previous research [7].

Single nucleotide polymorphisms (SNPs) occurring in the miRNA gene region may influence the function of specific miRNA molecules and the genetic variation, which are associated with cancer susceptibility through altering miRNA molecules expression [8-9]. Recently, miR-196a2C.T (rs11614913) and miR-499 A.G (rs3746444) have been reported to demonstrate the association with malignant tumors susceptibility [10–17]. For instance, Min et al. [11] demonstrates that the miRNA variants could affect the development of colorectal cancer in the Korean, while Georgeh et al. [17]. showed miR-196a2C.T (rs11614913)and miR-499 A.G (rs3746444) revealed significant risk for developing prostate cancer in North Indian. However, the consequences of these relevant studies remain incomprehensive and controversial. To the best of our knowledge, there is no systematic and comprehensive reports or studies regarding the impact of miR196a2 and miR-499 variants on overall cancer risk in world wide population. Hence, we performed a meta-analysis to clarify the associaton between the miR-196a2C.T (rs11614913)and miR-499 A.G (rs3746444) polymorphisms with cancer susceptibility.

MATERIALS AND METHODS

Publication search

We carried out a search in PubMed, ISI Web of Knowledge, EMBASE, Chinese National Knowledge Infrastructure(CNKI) databases for all relevant reports using the key words "microRNA 192" OR "microRNA-192" OR "miR-192" OR "rs11614913" OR "microRNA 499" OR "microRNA-499" OR "miR-499" OR "rs3746444") AND ("polymorphism" OR "SNP" OR "variation" OR "locus" OR "mutation") AND ("cancer" OR "tumor" OR "malignancy" OR "carcinoma" OR "neoplasm"(updated to Dec 30, 2016). The search was limited to English language papers and human subject studies. We evaluated potentially relevant publications by examining their titles and abstracts, thereafter all studies matching the eligible inclusion criteria were retrieved.

Selection criteria

The following criteria were used to select studies for further meta-analysis: (a) about the miR-196a2 rs11614913/miR-499 rs3746444 polymorphisms and cancer risk, (b) full-text study, (c) from a case-control designed study, (d) genotype frequencies available, (e) sufficient published data for estimating an odds ratio (OR) with 95% confidence interval (CI).

Accordingly, the following exclusion criteria were also used: (a) the design of the experiments were not casecontrol studies; (b) the source of cases and controls, and other essential information were not provided; (c) reviews and duplicated publications.

Data extraction

All data were independently abstracted in duplicate by two investigators (Yan and Zhang) using a standard protocol and data-collection form according to the inclusion criteria listed above. The following information was sought from each publication: the first author's name, year of publication, country of origin, ethnicity, cancer type, source of control (population- or hospital-based controls), genotyping method and number of cases and controls miR-196a2 C/T and/or miR-499 G/A genotypes, respectively (Table 1). Different ethnicity descents were categorized as Caucasian and Asian.

Statistical analysis

We first assessed the departure of frequencies of miRNA polymorphisms from expectation under Hardy-Weinberg equilibrium (HWE) for each study by using the goodness-of-fit test (chisquare or Fisher exact test) in controls. ORs corresponding to 95% CIs were calculated to access the strength of association between microRNA SNPs and cancer risks. Pooled ORs were obtained from combination of single study by heterozygote comparison (CT vs. CC for rs11614913; AG vs. AA for rs3746444), homozygote comparison (TT vs. CC for rs11614913; GG vs. AA for rs3746444), dominant model (TT + TC vs. CC for rs11614913; GG + AG vs. AA for rs3746444), recessive model (TT vs. CC + CT for rs11614913; GG vs. AG + AA for rs3746444) and allelic model (T vs. C for rs11614913; G vs. A for rs3746444) respectively. For each genetic comparison model, subgroup analysis according to ethnicity was investigated to estimate ethnic-specific ORs for Asian and Caucasian. Meanwhile stratified analyses by tumor type or control characteristics were also applied for each genetic comparison model.

Statistical heterogeneity between studies was checked by Cocharan's chi-square based *Q*-test [18] and quantified by I². If the *P*-value for heterogeneity was < 0.05, or if I² was \geq 50%, indicating substantial heterogeneity among studies, then a random-effect model using the DerSimonian and Laird method [31], which yielded wider CIs, was chosen to calculate the pooled OR; otherwise, a fixed-effect model using the Mantel-Haenszel method [19] was used. One-way sensitivity analyses were performed to assess the stability of the meta-analysis results [20]. Potential publication bias was estimated using Egger's linear regression test by visual inspection of the Funnel plot. All *P* value < 0.05 was used as an indication of potential publication bias [21].

All statistical analyses were carried out with the review manager version 5.2 (Revman; The Cochrane Collaboration, Oxford, UK). All P values in the metaanalysis were two-sided, and P value less than 0.05 were considered significant.

RESULTS

Characteristics of the studies

In total, 462 published studies were obtained though literature search, including the PubMed, EMBASE and

	Author	Year	Race	Cancer type	Control	Method	Case/control	Polymorphism site
1	Ahn [22]	2012	Asian	gastric cancer	РВ	PCR-RFLP	461/477	rs11614913, rs3746444
2	Alshatwi [23]	2012	Asian	Breast Cancer	РВ	PCR-RFLP	89/100	rs11614913, rs3746444
3	B.Zhou [24]	2011	Asian	Cervical Squamous Cell Carcinoma	РВ	PCR-RFLP	226/309	rs11614913, rs3746444
4	Bansal [25]	2014	Asian	breast cancer	PB	PCR-RFLP	121/164	rs11614913, rs3746444
5	Behnaz [26]	2016	Caucasian	НСС	PB	PCR	103/432	rs11614913
6	Brajušković [27]	2015	Caucasian	prostate cancer	PB	PCR-RFLP	355/312	rs11614913, rs3746444
7	Catucci [28]	2012	Caucasian	breast cancer	PB	PCR-RFLP	1894/2760	rs11614913, rs3746444
8	cheng [29]	2015	Asian	gastric cancer	HB	MassARRAY	363/969	rs3746444
9	Chu [30]	2012	Asian	Oral Cancer	PB	PCR-RFLP	470/425	rs11614913, rs3746444
10	D. Li [31]	2015	Asian	HCC	PB	RT-PCR	184/184	rs3746444
11	Dai [32]	2016	Asian	breast cancer	HB	MassARRAY	560/583	rs11614913, rs3746444
12	Deng [33]	2015	Asian	bladder cancer	PB	PCR-RFLP	159/298	rs11614913, rs3746444
13	Dominik [34]	2011	Caucasian	Breast Cancer	PB	PCR-RFLP	187/171	rs11614913
14	Dou [35]	2010	Asian	glioma	PB	PCR-RFLP	643/656	rs11614913
15	Eman [36]	2016	Caucasian	Hepatic/Renal Cancer	PB	RT-PCR	65/150	rs11614913, rs3746444
16	Gu [37]	2013	Asian	esophageal cancer	PB	PCR-RFLP	380/380	rs11614913, rs3746444
17	H. Chen [38]	2011	Asian	colorectal cancer	HB	PCR-LDR	126/407	rs11614913
18	H. Zhao [39]	2016	Asian	breast cancer	HB	RT-PCR	114/114	rs11614913
19	Hashemi [40]	2016	Asian	prostate cancer	PB	PCR-RFLP	169/182	rs11614913, rs3746444
20	Hikmet [41]	2011	Caucasian	HCC	РВ	PCR-RFLP	222/222	rs3746444
21	Hong [42]	2011	Asian	Lung Cancer	HB	PCR-RFLP	406/428	rs11614913
22	Hu [43]	2013	Asian	Glioma	HB	PCR-RFLP	680/690	rs11614913, rs3746444
23	J. Shi [44]	2015	Asian	gastric cancer	PB	RT-PCR	448/452	rs3746444
24	Kim [45]	2012	Asian	colorectal cancer	PB	PCR-RFLP	201/159	rs11614913, rs3746444
25	Kim [46]	2011	Asian	lung cancer	PB	PCR-RFLP	654/640	rs11614913
26	Kou [47]	2014	Asian	HCC	РВ	PCR-RFLP	271/532	rs11614913, rs3746444
27	Kshitij [48]	2010	Asian	gallbladder cancer	РВ	PCR-RFLP	230/230	rs11614913, rs3746444
28	Kuo [49]	2014	Asian	HCC	РВ	PCR-RFLP	188/377	rs11614913, rs3746444
29	Li [50]	2015	Asian	non-Hodgkin lymphoma	PB	RT-PCR	318/320	rs11614913
30	Linhare [51]	2012	Caucasian	Breast cancer	PB	TaqMan	388/388	rs11614913
31	LIU [52]	2010	Asian	HCC	HB	PCR-RFLP	310/222	rs11614913
32	Lv [53]	2013	Asian	colorectal cancer	PB	PCR-RFLP	353/540	rs11614913
33	M. Zhang [54]	2012	Asian	Breast Cancer	PB	PCR-RFLP	252/248	rs11614913
34	Masaaki [55]	2010	Asian	gastric cancer	PB	PCR-RFLP	552/697	rs11614913, rs3746444
35	Min [11]	2012	Asian	Colorectal Cancer	PB	PCR-RFLP	446/502	rs11614913, rs3746444
36	Morales [56]	2016	Caucasian	Breast cancer	PB	TaqMan	440/807	rs11614913

Table 1: Summary of published studies included

37	N. Wang [57]	2014	Asian	ESCC	PB	PCR-LDR	597/597	rs11614913
38	Ni [58]	2015	Asian	endometrial/ovarian cancer	РВ	PCR	141/100	rs11614913, rs3746444
39	Omrani [59]	2014	Asian	breast cancer	PB	PCR	236/203	rs11614913, rs3746444
40	P. Dikaiakos [60]	2015	Caucasian	colorectal cancer	РВ	PCR-RFLP	157/299	rs11614913
41	P. Li [61]	2014	Asian	Nasopharyngeal Carcinoma	PB	RT-PCR	1020/1006	rs11614913
42	P. Qi [62]	2015	Asian	breast cancer	PB	PCR-RFLP	321/290	rs11614913, rs3746444
43	Panagiotis [63]	2014	Caucasian	gastric cancer	HB	PCR-RFLP	163/480	rs11614913
44	Pavlakis [64]	2013	Caucasian	pancreatic cancer	HB	PCR-RFLP	93/122	rs11614913
45	Peng [65]	2010	Asian	gastric cancer	HB	PCR-RFLP	231/213	rs11614913
46	Qi [66]	2011	Asian	HCC	PB	PCR-LDR	361/391	rs11614913
47	Qu [67]	2014	Asian	ESCC	HB	PCR-RFLP	381/426	rs11614913
48	Rama [68]	2010	Asian	Bladder Cancer	PB	PCR-RFLP	212/250	rs11614913, rs3746444
49	Renata [69]	2012	Caucasian	colorectal cancer	PB	PCR-RFLP	197/212	rs11614913
50	Roshni [70]	2014	Asian	oral cancer	PB	PCR-RFLP	451/452	rs11614913
51	Serena [71]	2011	Caucasian	Lung Cancer	PB	RT-PCR	101/129	rs11614913, rs3746444
52	Shen [72]	2015	Asian	ESCC	РВ	Hapmap	1400/2185	rs11614913, rs3746444
53	Sushma [73]	2015	Caucasian	Oral Squamous Cell Carcinoma	РВ	PCR-RFLP	100/102	rs11614913, rs3746444
54	Tian [74]	2009	Asian	lung cancer	PB	PCR-RFLP	1058/1035	rs11614913, rs3746444
55	Wang [75]	2014	Asian	HCC	РВ	PCR-RFLP	152/304	rs3746444
56	Wu [76]	2013	Asian	gastric cancer	PB	PCR-RFLP	200/211	rs3746444
57	Yan [77]	2015	Asian	НСС	PB	PCR-RFLP	274/328	rs11614913, rs3746444
58	Z.Hu [78]	2008	Asian	breast cancer	PB	PCR-RFLP	1009/1093	rs11614913, rs3746444
59	Zhang [79]	2013	Asian	Acute lymphoblastic leukemia	РВ	TaqMan	570/673	rs11614913
60	Zhao [80]	2013	Asian	HCC	PB	PCR-RFLP	235/281	rs11614913, rs3746444
61	Zhou [81]	2014	Asian	HCC	PB	PCR-RFLP	266/281	rs11614913, rs3746444
62	Zhu [82]	2011	Asian	Colorectal Cancer	HB	RT-PCR	573/588	rs11614913

HB, hospital based; PB, population based; HCC, hepatocellular carcinoma; ESCC, esophageal squamous cell carcinomar; PCR-RFLP, polymerase chain reaction-restriction fragment length.

polymorphism; PCR-CTPP, polymerase chain reaction with confronting two-pair primers; LDR, ligation detection reaction.

CNKI database. Under conditions prescribed by the inclusion and exclusion criteria, 122 eligible studies (Figure 1) were retrieved, because they were no detailed evaluation. During data extraction, 62 eligible studies [22–83] were leaved, in which 56 and 37 studies were pooled for our meta-analysis, respectively (Figure 1). The characteristics of these selected studies are summarized in Table 1. Among all the included studies, there were 13 studies (hepatocellular cancer), 12 studies (breast), 7 studies (gastric), 6 studies (colorectal), 4 studies (lung), and 20 studies (other cancer types), and one (breast/ovarian cancer). There were 48 studies of Asian population, 14 studies of Caucasian population. Generally

speaking, 56 studies included in our meta-analysis with 21958 cases and 26436 controls, which were ultimately analyzed for miR-196a2C.T (rs11614913), 37 studies including 13759 cases and 17946 controls for miR-499 A.G(rs3746444).

Quantitative synthesis

miR-196a2C.T (rs11614913)

For miR-196a2C.T rs11614913 polymorphism, our mate-analysis contain 56 studies (21958 cases and 26436 controls). We observed the T allele frequency via different

ethnicities (Asian: 0.93, 95% CI = 0.91–0.96; Caucasian: 0.96, 95% CI = 0.90–1.02).

In the overall analysis, our mate-analysis results manifested a statistically significant association between the miR-196a2C.T rs11614913 and the reduced risks of cancers (OR = 0.93, 95% CI = 0.91–0.96, $P_H < 0.00001$ for T vs. C), homozygote comparison (OR = 0.88, 95% CI = 0.83–0.93, $P_H < 0.00001$ for TT vs. CC), dominant model (OR = 0.92, 95% CI = 0.89–0.96, $P_H < 0.00001$ for TT + CT vs. CC) and recessive model (OR = 0.94, 95% CI = 0.90–0.98, $P_H < 0.00001$ for TT vs. CC + CT) (Supplementary Table 1).

In subgroup analysis by cancer types, we found the significant associations between the miR-196a2C.T rs11614913 and colorectal cancer (OR = 1.21, 95% CI = 1.11–1.33, $P_H < 0.00001$ for T vs. C; OR = 1.45, 95% CI = 1.21–1.74, $P_H < 0.00001$ for TT vs.CC; OR = 1.25, 95% CI = 1.06–1.46, $P_H < 0.00001$ for CT vs. CC; OR = 1.23, 95% CI = 1.05–1.43, $P_H < 0.00001$ for TT + TC vs. CC; OR = 1.72, 95% CI = 1.50–1.98, $P_H < 0.00001$ for TT vs. CC/TC); lung cancer (OR = 0.89, 95% CI = 0.82–0.97, $P_H = 0.008$ for T vs.C; OR = 0.79, 95%

CI = 0.67-0.94, $P_{H} = 0.26$ for TT vs.CC; OR = 0.84, 95% CI = 0.74-0.96, $P_{H} = 0.2$ for TT vs. CC + TC); gastric cancer (OR = 0.77, 95% CI = $0.69-0.85, P_{H} < 0.00001$ for T vs. C; OR = 0.54, 95% CI = 0.45–0.66, $P_{\rm H} < 0.00001$ for TT vs. CC; OR = 0.63, 95% CI = 0.52–0.75, $P_{\rm H} < 0.00001$ for CT vs. CC; OR = 0.66, 95% CI = 0.56–0.77, $P_{\rm H} <$ 0.00001 for TT + CT vs. CC; OR = 0.76, 95% CI = 0.65-0.89, $P_{\mu} < 0.00001$ for TT vs. CC + TC). In addition, we also found the decreased risks in other cancer types (OR = 0.86, 95% CI = 0.82–0.90, $P_{\rm H}$ < 0.00001 for T vs. C; OR = 0.90, 95% CI = 0.83–0.98, $P_{\rm H} < 0.00001$ for TT vs. CC; OR = 0.90, 95% CI = 0.84–0.97, $P_{\rm H} < 0.00001$ for TT + CT vs. CC; OR = 0.87, 95% CI = 0.81–0.93, P_{H} < 0.00001 for TT vs. CC + TC) (Figure 2). Subgroup analysis by the ethnicity revealed a significant association in the comparison of T vs.C (OR = 0.93, 95% CI = 0.91-0.96, $P_{\rm H} < 0.00001$), TT vs. CC (OR = 0.87, 95% CI = 0.82–0.92, $P_{\rm H} <$ 0.00001), TT vs. CC + TC (OR = 0.91, 95% CI = 0.87–0.95, $P_{\rm H} < 0.00001$) in the Asian (Figure 3). Subgroup analysis by the source of control indicated a decreased risk in hospital based study, as showed in Supplementary Table 1.




Figure 1: Flow chart of the study selection process.

Study or Subgroup	Experim Events		Cont Events		Weight	Odds Ratio M-H, Fixed, 95% Cl	Odds Ratio M-H, Fixed, 95% Cl
3.1.1 Breast							
Alshatwi 2012	98	100	96	100	0.0%	2.04 [0.37, 11.41]	
Bansal 2014	53	121	80	164	0.9%	0.82 [0.51, 1.31]	
Catucci 2012	1086	1894	1623	2760	13.1%	0.94 [0.84, 1.06]	-
Dai 2015	363	560	428	583	3.4%	0.67 [0.52, 0.86]	
Dominik 2011 H.Zhao 2016	119 83	187 114	113 86	171	1.0%	0.90 [0.58, 1.39] 0.87 [0.48, 1.58]	
Linhare 2012	294	388	261	388	1.5%	1.52 [1.11, 2.08]	
M. Zhang 2011	234	252	226	248	0.3%	1.54 [0.78, 3.04]	
Morales 2016	248	440	465	807	3.3%	0.95 [0.75, 1.20]	+
Omrani 2014	18	236	25	203	0.6%	0.59 [0.31, 1.11]	
P.Qi 2015	287	321	273	290	0.7%	0.53 [0.29, 0.96]	
Subtotal (95% CI)	201	4613	210	5828	25.4%	0.92 [0.85, 1.00]	
Total events	2886		3676				
Heterogeneity: Chi [#] =		: 10 (P =		≓= 60%			
Test for overall effect.							
3.1.2 Colorectal							
H.Chen 2011	99	126	313	407	0.7%	1.10 [0.68, 1.79]	
Lv 2013	337	353	422	540	0.4%	5.89 [3.43, 10.12]	
Min 2012	326	446	402	502	2.4%	0.68 [0.50, 0.91]	-
P. Dikaiakos 2015	266	157	138	299	i nesse	Not estimable	
Renata 2012	115	197	125	212	1.2%	0.98 [0.66, 1.45]	T
Zhu 2011	140	573	121	588	2.1%	1.25 [0.95, 1.64]	
Subtotal (95% CI)	10000205	1852	1222/101	2548	6.7%	1.23 [1.05, 1.43]	•
Total events Heterogeneity: Chi² =				l²= 929	6		
Fest for overall effect	Z= 2.57 (f	P = 0.01)					
Behnaz 2016	75	103	306	432	0.7%	1.10 [0.68, 1.78]	-
Eman 2016	42	65	70	432	0.3%	2.09 [1.14, 3.81]	
Kim1 2012	125	159	156	201	0.3%	1.06 [0.64, 1.75]	+
Kou 2014	187	271	407	532	2.0%	0.68 [0.49, 0.95]	-
Kuo 2014	147	188	267	377	0.9%	1.48 [0.98, 2.23]	
Liu 2010	232	310	180	222	1.2%	0.69 [0.45, 1.06]	
Qi 2011	279	361	299	391	1.5%	1.05 [0.75, 1.47]	+
Yan 2015	228	274	301	328	1.1%	0.44 [0.27, 0.74]	
Zhao 2013	215	235	158	281	0.3%	8.37 [5.00, 14.01]	· · · · · · · · · · · · · · · · · · ·
Zhou 2014	173	266	215	281	1.7%	0.57 [0.39, 0.83]	
Subtotal (95% CI)	1022200	2232		3195	10.4%	1.07 [0.94, 1.22]	•
Total events	1703		2359				
Test for overall effect 3.1.4 Lung Hong 2011	320	406	332	428	1.6%	1.08 [0.77, 1.50]	-
Kim2 2010	467	654	485	640	3.3%	0.80 [0.62, 1.02]	+
Serena 2011	66	101	71	129	0.5%	1.54 [0.90, 2.64]	
	66 805	101 1058	71 826	129 1035	0.5% 4.6%	1.54 [0.90, 2.64] 0.81 [0.65, 0.99]	-
Tian 2009 Subtotal (95% CI)	805		826				-
Tian 2009 Subtotal (95% CI) Total events	805 1658	1058 2219	826 1714	1035 2232	4.6%	0.81 [0.65, 0.99]	-
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi ² =	805 1658 6.91, df=	1058 2219 3 (P = 0.	826 1714 07); I² = 1	1035 2232	4.6%	0.81 [0.65, 0.99]	•
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi ^a = Test for overall effect:	805 1658 6.91, df=	1058 2219 3 (P = 0.	826 1714 07); I² = 1	1035 2232	4.6%	0.81 [0.65, 0.99]	-
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [#] = Test for overall effect: 3.1.5 Gastric	805 1658 6.91, df=	1058 2219 3 (P = 0.	826 1714 07); I² = 1	1035 2232	4.6%	0.81 [0.65, 0.99]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi ^a = Test for overall effect: 3.1.5 Gastric Ahn 2012	805 1658 6.91, df = Z = 1.77 (f	1058 2219 3 (P = 0. P = 0.08)	826 1714 07); I ^e = 9	1035 2232 57%	4.6% 10.0%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 3.1.5 Gastric Ahn 2012 Masaaki 2010	805 1658 6.91, df= Z = 1.77 (f 361	1058 2219 3 (P = 0. P = 0.08) 461	826 1714 07); I ^e = 1 355	1035 2232 57% 477	4.6% 10.0 % 1.8%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi≌ = Test for overall effect 3.1.5 Gastric Ahn 2012 Masaaki 2010 Panagiotis 2014	805 1658 6.91, df= Z = 1.77 (f 361 447	1058 2219 3 (P = 0. P = 0.08) 461 552	826 1714 07); I* = 1 355 573	1035 2232 57% 477 697 480 213	4.6% 10.0% 1.8% 2.2%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [#] = Test for overall effect 3.1.5 Gastric Ahn 2012 Masaaki 2010 Panagiotis 2014 Peng 2010	805 1658 6.91, df = Z = 1.77 (f 361 447 61	1058 2219 3 (P = 0. P = 0.08) 461 552 163	826 1714 07); I ^a = 1 355 573 401	1035 2232 57% 477 697 480	4.6% 10.0% 1.8% 2.2% 3.0%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi≇ = Test for overall effect 3.1.5 Gastric Ahn 2012 Massaki 2010 Panagiotis 2014 Peng 2010 Subtotal (95% CI)	805 1658 6.91, df = Z = 1.77 (f 361 447 61	1058 2219 3 (P = 0. P = 0.08) 461 552 163 213	826 1714 07); I ^a = 1 355 573 401	1035 2232 57% 477 697 480 213	4.6% 10.0% 1.8% 2.2% 3.0% 1.3%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect 3.1.5 Gastric Masaaki 2010 Panagolotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] =	805 1658 6.91, df = Z = 1.77 (f 361 447 61 137 1006 93.72, df =	1058 2219 3 (P = 0. P = 0.08) 461 552 163 213 1389 = 3 (P < (826 1714 07); P = 1 355 573 401 157 1486 0.00001)	1035 2232 57% 477 697 480 213 1867	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types	805 1658 6.91, df = Z = 1.77 (f 361 447 61 137 1006 93.72, df =	1058 2219 3 (P = 0. P = 0.08) 461 552 163 213 1389 = 3 (P < (826 1714 07); I ^a = 9 355 573 401 157 1486 0.00001) 001)	1035 2232 57% 477 697 480 213 1867	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97] 0.66 [0.56, 0.77]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types	805 1658 6.91, df = Z = 1.77 (f 361 447 61 137 1006 93.72, df = Z = 5.05 (f 180	1058 2219 3 (P = 0. P = 0.08) 461 552 163 213 1389 = 3 (P < 0 P < 0.000	826 1714 07); I ^a = 9 365 573 401 157 1486 0.00001) 001) 251	1035 2232 57% 477 697 480 213 1867 ; I* = 979 309	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2% 6	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97] 0.66 [0.56, 0.77]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi≇ = Test for overall effect 3.1.5 Gostric Ahn 2012 Massaki 2010 Panagiotis 2014 Peng 2010 Subtotal (95% CI) Total events Heterogeneity: Chi≇ = Test for overall effect 3.1.6 Other Types B Zhou 2011	805 1658 6.91, df = Z = 1.77 (f 361 447 61 137 1006 93.72, df = Z = 5.05 (f	1058 2219 3 (P = 0. P = 0.08) 461 552 163 213 1389 = 3 (P < 0.00)	826 1714 07); I ^a = 9 355 573 401 157 1486 0.00001) 001)	1035 2232 57% 477 697 480 213 1867 ; I² = 979	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.59, 1.39] 0.20 [0.59, 1.39]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Brajušković 2015 Chu 2012	805 1658 6.91, df =: Z = 1.77 (f 361 447 61 137 1006 93.72, df = Z = 5.05 (f 180 80 413	1058 2219 3 (P = 0. P = 0.08) 461 552 163 213 1389 = 3 (P < (P < 0.00) 226 355 470	826 1714 07); I* = 1 355 573 401 157 1486 0.00001) 001) 251 208 338	1035 2232 57% 477 697 480 213 1867 (1° = 979 309 353 425	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2% 6 1.0% 3.8% 1.0%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.59, 1.39] 0.20 [0.15, 0.28] 1.86 [1.30, 2.68]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi≇ = Test for overall effect 3.1.5 Gestric Ahn 2012 Massaki 2010 Panagiotis 2014 Peng 2010 Subtotal (95% CI) Total events Heterogeneity: Chi² = Test for overall effect 3.1.6 Other Types B.Zhou 2011 Brajušković 2015 Chu 2012 Deng 2015	805 1658 6.91, df=: Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118	1058 2219 3 (P = 0. P = 0.08) 461 552 163 213 1389 = 3 (P < (P < 0.00) 226 355 470 159	826 1714 07); * = 1 365 573 401 157 1486 0.00001) 001) 251 208 338 242	1035 2232 57% 477 697 480 213 1867 ; ₱ = 979 309 353 425 298	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2% 6 1.0% 1.0%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97] 0.66 [0.56, 0.77] 0.90 [0.59, 1.39] 0.20 [0.15, 0.28] 1.86 [1.30, 2.68] 0.67 [0.42, 1.05]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagolotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Braiµšković 2015 Chu 2012 Deng 2015 Dou 2010	805 1658 6.91, df=: Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118 532	1058 2219 3 (P = 0. P = 0.08) 461 552 163 213 1389 = 3 (P < 0. P < 0.000 226 355 470 159 643	826 1714 07); I* = 1 365 573 401 157 1486 0.00001) 001) 251 208 338 242 513	1035 2232 57% 477 697 480 213 1867 ; * = 979 309 353 425 298 656	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2% 6 1.0% 3.8% 1.0% 1.0% 2.0%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.20 [0.15, 0.28] 1.86 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi¤ = Test for overall effect: 3.1.5 Gastric Ahn 2012 Massaki 2010 Panagiotis 2014 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi¤ = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Brajušković 2015 Chu 2012 Deng 2015 Dou 2010 Su 2013	805 1658 6.91, df=: Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118 532 302	1058 2219 3 (P = 0.08) 461 552 163 213 1389 = 3 (P < 0.000 226 355 470 159 643 380	826 1714 07); I* = 1 355 573 401 157 1486 0.00001) 001) 251 208 338 242 513 283	1035 2232 57% 477 480 213 1867 ; I* = 979 309 353 425 298 656 6380	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2% 6 1.0% 1.0% 1.0% 1.0% 1.3%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.59, 1.39] 0.20 [0.15, 0.28] 1.86 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi≆ = Test for overall effect 3.1.5 Gestric Ahn 2012 Massaki 2010 Panagiotis 2014 Peng 2010 Subtotal (95% CI) Total events Heterogeneity: Chi≆ = Test for overall effect 3.1.6 Other Types B.Zhou 2011 Brajušković 2015 Chu 2012 Deng 2015 Dou 2013 Hasherni 2018	805 1658 6.91, df= : Z = 1.77 (f 361 447 61 137 1006 93.72, df= Z = 5.05 (f 180 80 413 118 532 302 105	1058 2219 3 (P = 0. P = 0.08) 461 552 163 213 1389 = 3 (P < (P P < 0.000 226 355 470 159 643 380 169	826 1714 07); I ² = 5 573 401 157 1486 0.00001) 001) 251 208 338 242 513 255 513 208 338 242 513 208 318 208 208 208 208 318 208 208 208 208 208 208 208 20	1035 2232 57% 477 697 480 213 1867 ; I ² = 979 309 353 425 298 656 380 865 380 182	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2% 6 1.0% 1.0% 2.0% 1.0% 2.0% 1.0% 2.0%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.86 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 1.20 [0.78, 1.85]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagolöts 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Brajušković 2015 Chu 2012 Deng 2015 Dou 2010 Gu 2013 Hashemi 2016 Hu 2013	805 1658 6.91, df = ' Z = 1.77 (f 361 447 61 137 1006 93.72, df = Z = 5.05 (f 180 80 413 118 532 302 105	1058 2219 3 (P = 0. P = 0.08) 461 552 163 213 1389 = 3 (P < 0.000 226 355 470 159 643 380 169 680	826 1714 07); # = 5 355 573 401 157 1486 1.00001) 001) 251 208 338 242 513 263 105 552	1035 2232 57% 477 697 4807 213 1867 ; P = 979 309 353 425 2988 656 380 1825 2988 656 380	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2% 6 1.0% 1.0% 1.0% 1.0% 1.0% 1.3% 0.9% 3.5%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [1.00, 28] 1.86 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 0.67 [0.52, 0.86]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi≇ = Test for overall effect: 3.1.5 Gestric Ahn 2012 Massaki 2010 Panagiotis 2014 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi≇ = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Deng 2015 Dou 2013 Hashemi 2016 Hu 2013 Kahltij 2010	805 1658 6.91, df=' Z=1.77 (f 361 447 61 137 106 93.72, df=' Z=5.05 (f 180 80 413 118 532 302 105 495 111	1058 2219 3 (P = 0. P = 0.08) 461 552 163 1389 2 3 (P < 0.00) 2 266 355 4 700 159 643 380 169 643 3 800 230	826 1714 (07); I ^a = 1 355 573 401 157 1486 0.00001) 001) 251 208 338 242 251 208 338 242 251 208 338 243 261 208 338 242 251 208 338 243 263 265 552 513 263 263 265 552 513 263 263 265 552 513 265 552 513 265 553 555 557 573 555 573 573 573 573 57	1035 2232 57% 477 697 480 213 213 1867 213 213 213 213 213 213 213 213 213 213	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2% 6 1.0% 1.0% 1.0% 1.0% 2.0% 3.5% 0.9% 3.5%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.86 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 1.20 [0.78, 1.85] 0.67 [0.52, 0.86] 0.67 [0.52, 0.86] 0.54 [0.23, 0.50]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [#] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Heterogeneity: Chi [#] = Total events Heterogeneity: Chi [#] = Heterogeneity: Chi [#] = Total events Heterogeneity: Chi [#] = Heterogeneity: Chi [#] = Total events Heterogeneity: Chi [#] = Total events Heterogeneity: Chi [#] = Total events Heterogeneity: Chi [#] = Total events Heterogeneity: Chi [#] = Heterogeneity: Chi [#] =	805 1658 6.91, df = : Z = 1.77 (f 361 447 61 137 1006 93.72, df = Z = 5.05 (f 180 80 413 118 532 302 105 495 111 257	1058 2219 3 (P = 0. 08) 461 552 163 213 1389 2 3 (P < (P < 0.000 2266 355 5 226 355 643 355 643 169 680 230 318	826 1714 07); I ^a = 1 355 573 401 157 1486 0.00001) 101) 251 251 258 242 513 283 283 283 283 283 283 283 28	1035 2232 57% 477 697 213 1867 213 1867 (P=979 309 353 3425 298 656 650 880 182 690 230 320	4.6% 10.0% 1.8% 3.0% 1.3% 8.2% 6 1.0% 1.0% 1.0% 1.0% 1.0% 1.3% 0.9% 3.5% 2.0% 1.2%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.64 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [1.02, 0.8] 1.86 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 0.76 [0.52, 0.86] 0.44 [0.23, 0.50] 0.44 [0.41, 0.98]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 BraiµšKavić 2015 Chu 2012 Deng 2015 Dou 2010 Gu 2013 Hashemi 2016 Hu 2013 Kshitij 2010 Li 2015	805 1658 6.91, df=' Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118 502 302 105 495 111 257 469	1058 2219 3 (P = 0. 0.8) 4611 552 213 1389 23 (P < (0.00) 2266 553 200 200 255 4700 159 < 0.000 256 433 380 643 380 643 380 318 597	826 1714 1714 07); P = 1 365 573 401 157 1486 0.00001) 001) 251 208 338 242 513 242 513 242 513 242 513 242 513 242 513 242 513 242 513 242 513 242 513 513 513 513 513 513 513 513	1035 2232 57% 477 697 480 213 1867 480 213 1867 9353 425 298 656 6380 826 859 230 3200 230	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2% 6 1.0% 3.8% 5.0% 2.0% 2.0% 2.0% 2.2%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.69, 0.123] 0.64 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.86 [1.30, 2.68] 0.77 [0.42, 1.05] 1.34 [10, 1, 1.76] 1.33 [0.95, 1.86] 0.67 [0.52, 0.86] 0.52 (0.84] 0.52 (0.85, 0.50] 1.48 [0.90, 1.54]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi≇ = Test for overall effect: 3.1.5 Gestric Ahn 2012 Massaki 2010 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Subtotal (95% CI) Total events Heterogeneity: Chi≇ = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Deng 2015 Dou 2013 Hashemi 2016 Hu 2013 Kahitij 2010 Li 2015 N. Wang 2015 Ni 2015	805 1658 6.91, df = : Z = 1.77 (f 361 447 61 137 137 2 = 5.05 (f 180 80 413 118 532 302 105 495 111 257 465 122	1058 2219 3 (P = 0. P = 0.08) 4611 552 163 213 1389 2266 355 470 159 < 0.001 159 < 0.001 159 643 380 169 643 380 169 0230 318 597 141	826 1714 1714 365 573 401 157 1486 0.00001) 001) 2511 208 338 242 208 338 242 208 338 245 552 169 278 452 77	1035 2232 57% 477 697 480 213 1867 480 213 1867 309 353 425 298 656 380 182 656 380 230 230 230 100	4.6% 10.0% 2.2% 3.0% 1.3% 8.2% 6 6 6	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.42 [0.69, 1.23] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.36 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 1.20 [0.78, 1.85] 0.67 [0.52, 0.86] 0.34 [0.23, 0.50] 0.44 [0.41, 0.98] 1.18 [0.90, 1.54]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B Zhou 2011 Parajuškavić 2015 Chu 2012 Deng 2015 Dou 2010 Gu 2013 Hashemi 2016 Hu 2013 Kshitij 2010 Lj 2015 N. Wang 2015 N. Wang 2015 N. Wang 2015 N. Wang 2015 N. U 2014	805 1658 6.91, df= Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118 532 302 105 495 111 257 469 122 811	1058 2219 3 (P = 0. 0.8) 461 552 163 213 133 2139 2 3 (P < (0 226 355 2 < 0.000 226 355 470 159 643 380 0230 2159 643 380 230 231 89 680 2319	826 1714 1714 1714 355 573 401 157 1486 0.00001) 251 208 338 328 328 328 328 328 328 32	1035 2232 57% 477 697 480 2137 1137 1137 1137 1137 1137 1137 209 209 200 2300 2300 2300 2300 2300 23	4.6% 10.0% 2.2% 3.0% 8.2% 6 6 6 6 7.0% 3.8% 1.0% 5.0% 2.0% 2.2% 0.3% 3.8%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.24 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [1.02, 0.8] 1.86 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 0.67 [0.52, 0.86] 0.54 [0.23, 0.50] 0.54 [0.41, 0.98] 1.18 [0.90, 1.54] 1.29 [0.98, 3.75] 1.07 [0.87, 1.33]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Braijušković 2015 Chu 2012 Deng 2015 Dou 2015 Hu 2015 Ni 2015 Ni 2015 P. Li 2014 Paviakis 2013	805 1658 6.91, df = ' Z = 1.77 (f 361 447 61 137 1006 93.72, df = Z = 5.05 (f 180 80 80 413 118 532 105 495 545 111 257 469 122 105 111 257 105 115 115 115 115 115 115 115	1058 2219 3 (P = 0.) P = 0.08) 461 552 163 213 1389 = 3 (P < (0.00) 2266 355 355 355 355 355 355 355 3	826 1714 1714 365 573 401 1486 0.00001) 001) 2511 208 338 242 552 169 278 862 77 788 8452 77 788 8452 169 278 189 189 189 189 189 189 189 18	1035 2232 57% 477 697 480 213 1867 7 = 979 309 353 353 353 353 353 353 353 353 353 298 656 0230 230 230 230 210 100 100 100 100 100 100 100 100 10	4.6% 10.0% 1.8% 2.2% 3.0% 8.2% 6 6 6 6 6 7.0% 2.0% 1.0% 2.0% 1.0% 2.0% 2.0% 0.3% 3.8% 0.3%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [1.30, 2.68] 0.76 [0.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 1.20 [0.78, 1.85] 0.67 [0.52, 0.86] 0.34 [0.23, 0.50] 0.44 [0.41, 0.98] 1.18 [0.00, 1.54] 1.82 [0.98, 3.75] 1.76 [0.87, 1.33] 0.88 [0.38, 1.99]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [#] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2015 Dou 2010 Subtotal Pass Extension 2015 Dou 2010 Su 2013 Hashemi 2016 Hu 2013 Kahitig 2010 Li 2015 N. Wang 2015	805 1658 6.91, df = : Z = 1.77 (f 361 447 61 137 137 2 = 5.05 (f 180 80 413 118 532 302 105 495 111 257 469 122 811 81 81 225	1058 2219 2219 3 (P = 0.08) 461 552 163 213 1389 2 3 (P < 0.00) 226 355 C 0.000 169 643 380 169 643 380 169 643 380 169 141 1020 381	826 1714 1714 355 573 401 157 1486 00001) 001) 251 208 242 513 338 242 513 20001) 00001 201 201 202 105 522 105 522 105 523 105 525 105 525 105 525 105 525 105 525 105 525 105 525 105 525 105 525 105 525 105 525 105 525 105 525 105 527 105 527 105 525 105 527 105 527 105 527 105 527 105 527 105 527 105 105 527 105 278 8 105 277 778 8 108 293 293 293 293 293 293 293 297 297 298 297 297 298 297 297 297 297 297 297 297 297	1035 2232 57% 477 697 480 213 11867 298 656 690 182 298 656 690 182 690 182 0320 230 320 100 1006 122	4.6% 10.0% 1.8% 2.2% 3.0% 8.2% 8.2% 6 6 6 6 6 6	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.24 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [1.0, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 0.47 [0.22, 0.86] 0.34 [0.23, 0.50] 0.34 [0.23, 0	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Trajušković 2015 Chu 2012 Deng 2015 Dou 2010 GU 2013 Hashemi 2016 Hu 2013 Kshitij 2010 Li 2015 N. Wang 2014 Paviakis 2013 Gu 2014 Rama 2010	805 1658 6.91, df = ' Z = 1.77 (f 361 447 61 137 1006 93.72, df = Z = 5.05 (f 180 80 413 118 532 302 102 111 255 136	1058 2219 3 (P = 0.) P = 0.08) 461 552 163 11389 213 11389 23 (P < (P < 0.000 2266 355 470 159 2266 433 380 169 643 380 169 643 380 230 230 230 231 242 255 245 255 255 255 255 255 255 255	826 1714 1714 355 573 401 157 1486 0.00001) 001) 2511 208 338 242 208 338 242 208 338 242 277 788 108 293 141 148 148 148 148 148 148 148	1035 2232 57% 477 697 480 213 1867 213 1867 309 353 353 425 298 656 6300 822 690 230 320 320 230 1822 690 1822 690 1822 690 1822 690 1822 690 1822 690 1822 800 800 800 800 800 800 800 800 800	4.6% 10.0% 1.8% 2.2% 3.0% 8.2% 6. 6 1.0% 5.8% 1.0% 5.5% 2.0% 0.3% 2.1% 0.3% 0.3% 2.1%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.36 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 0.67 [0.52, 0.86] 0.54 [0.23, 0.50] 0.44 [0.41, 0.98] 1.18 [0.90, 1.54] 1.92 [0.98, 3.75] 1.07 [0.87, 1.33] 0.88 [0.38, 1.99] 0.22 [0.68, 1.23] 1.38 [0.95, 2.01]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Brajušković 2015 Chu 2012 Deng 2015 Dou 2010 Gu 2013 Kshitij 2010 Li 2015 Ni 2015 Ni 2014 Pavlakis 2013 Qu 2014 Rama 2010 Roschni 2014	805 1658 6.91, df = : Z = 1.77 (f 361 447 61 137 1006 93.72, df = Z = 5.05 (f 180 80 80 413 118 532 105 495 111 257 469 122 811 111 255 136 233	1058 2219 2219 3 (P = 0.08) 461 552 163 213 1389 2266 355 0.000 2266 355 0.000 2266 355 0.000 2266 355 0.000 2266 355 1389 2226 355 1389 2226 355 213 1389 2226 355 213 1389 226 355 213 1389 226 355 213 1389 226 355 213 1389 226 355 213 1389 226 355 213 1389 226 355 213 1389 226 355 213 1389 226 355 213 1389 226 355 213 1389 226 355 235 210 159 200 159 226 355 230 159 230 230 159 230 230 230 230 230 230 230 230	826 1714 1714 365 573 401 157 1486 000001) 001) 001) 2511 2088 242 513 388 242 513 388 242 513 169 278 8452 77 788 8452 169 278 169 278 169 278 169 278 169 278 169 278 169 278 169 278 169 278 169 278 169 169 169 169 169 169 169 169	1035 2232 57% 477 697 480 213 1867 7 = 979 309 353 353 3425 298 656 656 380 320 230 230 230 230 2426 2426 259 452	4.6% 10.0% 1.8% 2.2% 3.0% 4.3% 8.2% 6 6 6 6 6 6 6 6 7 7 8.2% 5.20%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.36 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [101, 1.76] 1.33 [0.95, 1.86] 1.20 [0.78, 1.85] 0.67 [0.52, 0.86] 0.34 [0.23, 0.50] 0.44 [0.41, 0.98] 1.18 [0.90, 1.54] 1.82 [0.98, 3.75] 1.07 [0.87, 1.33] 0.88 [0.38, 1.99] 0.92 [0.68, 1.23] 1.38 [0.95, 2.01] 1.38 [0.95, 2.01]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Peng 2010 Subtotal (95% CI) Subtotal (805 1658 6.91, df= Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118 532 302 105 495 111 257 469 1257 485 111 257 485 111 257 485 111 257 485 112 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 1137 257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 1257 136 136 136 137 137 137 137 137 137 137 137	1058 2219 3 (P = 0.0) 9 = 0.08) 461 552 163 1389 2 3 (P < (> < 0.00) 226 355 5 355 5 355 5 355 5 470 543 380 230 880 230 318 169 680 230 318 169 1643 381 120 246 1643 381 120 246 1643 381 120 246 246 256 257 266 266 267 267 267 267 267 267 267 26	826 1714 1714 365 573 401 157 1486 0.00001) 001) 251 208 338 242 552 552 552 552 552 552 552	1035 2232 57% 477 697 480 213 1867 213 1867 213 1867 309 353 353 425 298 656 656 650 2300 2300 182 690 2300 1006 182 2426 2426 2426 2426 2426 2426 2426 24	4.6% 10.0% 1.8% 2.2% 3.0% 8.2% 8.2% 6 6 6 6 6 6 6 6 6 7.0% 1.0% 2.0% 2.0% 3.5% 2.0% 3.5% 2.0% 3.8% 0.3% 3.8% 0.3% 5.2% 3.8% 2.0% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.24 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [1.02, 0.8] 1.86 [1.30, 2.68] 0.67 [10.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 0.67 [0.52, 0.86] 0.34 [0.23, 0.50] 0.64 [0.41, 0.98] 1.18 [0.90, 1.54] 1.92 [0.88, 3.75] 1.07 [0.87, 1.33] 0.88 [0.38, 1.99] 0.92 [0.68, 1.23] 1.38 [0.95, 2.01] 1.28 [0.98, 1.66] 0.42 [0.49, 0.97]	
Serena 2011 Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [#] = Test for overall effect: 3.1.5 Gastric Ahn 2012 Masaaki 2010 Panagiotis 2014 Peng 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [#] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Brajušković 2015 Chu 2012 Dong 2015 Dong 2015 Dong 2015 Dong 2015 Dong 2015 N. Wang 2015 N. Wang 2015 N. Wang 2015 N. Wang 2015 N. Wang 2015 N. Wang 2015 N. U 2014 Pavlakis 2013 Washitij 2014 Rama 2010 Roshni 2014 Rama 2015 Sushma 2015 Sushma 2015	805 1658 6.91, df=' Z=1.77 (f 361 447 61 137 1006 93.72, df=' Z=5.05 (f 180 80 413 118 302 105 495 111 255 136 233 1105 233 1105	1058 2219 3 (P = 0.) P = 0.08) 461 552 163 213 1389 226 27 226 27 355 470 159 226 43 380 230 318 943 380 230 318 957 141 1020 93 381 1212 212 219	826 1714 1714 1717 1717 1717 1486 0.00001) 157 1486 0.00001) 157 1486 0.00001) 157 1486 157 157 1486 157 1486 157 157 1486 157 157 157 1486 157 157 157 157 157 157 157 157	1035 2232 57% 477 697 480 213 1867 213 1867 7 = 979 309 353 353 353 353 353 353 353 353 298 656 630 230 320 230 230 2426 298 202 212 212 212 212 212 212 212 212 212	4.6% 10.0% 1.8% 2.2% 3.0% 8.2% 6. 6 6 6 6 6 7.0% 2.0% 2.0% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 5.2% 0.3% 5.2% 0.3% 5.2% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.86 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 0.67 [0.52, 0.86] 0.54 [0.23, 0.50] 0.46 [0.14, 0.98] 1.18 [0.90, 1.54] 1.92 [0.98, 3.75] 1.71 [0.77, 1.33] 0.88 [0.38, 1.99] 0.92 [0.68, 1.23] 1.38 [0.95, 2.01] 1.28 [0.99, 1.63] 0.95 [0.95, 0.97]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi¤ = Test for overall effect: 3.1.5 Gestric Ahn 2012 Aasaaki 2010 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi¤ = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Brajušković 2015 Chu 2012 Deng 2015 Deng 2015 Ni 2015 Ni 2014 Rama 2016 Qu 2013 Qu 2014 Rama 2010 Roshni 2014 Shen 2015 Sushma 2013 Sushma 2015 Sushma 2015 Sushma 2015 Sushma 2015 Sushma 2013 Sushma 2015 Sushma 2015 Sushma 2015 Sushma 2013 Sushma 2015 Sushma 2013 Sushma 2015 Sushma 2015 Sushma 2015 Sushma 2013 Sushma 2015 Sushma 2015 Sushma 2015 Sushma 2015 Sushma 2015 Sushma 2013 Sushma 2015 Sushma 2013	805 1658 6.91, df= Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118 532 302 105 495 111 257 469 1257 485 111 257 485 111 257 485 111 257 485 112 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 257 485 1136 1137 257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 485 1136 1257 1257 136 136 136 137 137 137 137 137 137 137 137	1058 2219 2219 3 (P = 0.08) 461 552 163 213 1389 2266 355 2 40.001 2266 355 2 40.001 159 643 380 169 643 380 380 380 381 1020 381 212 1141 1020 381 203 381 203 381 203 381 203 381 203 381 203 381 203 381 203 203 203 203 203 203 203 203	826 1714 1714 365 573 401 157 1486 0.00001) 001) 251 208 338 242 552 552 552 552 552 552 552	1035 2232 57% 477 697 480 213 1967 213 1967 309 353 1967 856 656 656 800 300 230 3200 230 3200 1006 102 2426 2597 202 212 212 212 212 212 212 212 212 212	4.6% 10.0% 1.8% 2.2% 3.0% 1.3% 8.2% 6 6 6 6 6 6 6 7 7 8.2% 5 8.5% 5 5% 5	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 1.20 [0.78, 1.85] 0.67 [0.52, 0.86] 0.34 [0.23, 0.50] 0.44 [0.41, 0.98] 1.18 [0.90, 1.54] 1.19 [0.98, 3.75] 1.07 [0.87, 1.33] 0.88 [0.98, 1.99] 0.92 [0.68, 1.23] 1.88 [0.95, 2.01] 1.22 [0.98, 1.66] 0.52 [0.68, 0.97] 1.22 [0.98, 0.57] 1.22 [0.98, 0.57] 1.20 [0.81, 1.43]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Deng 2015 Dou 2010 GU 2013 Hashemi 2016 Hu 2013 Kshifti 2010 Li 2015 N.Wang 2015 N.Wang 2015 N.Wang 2015 N.Wang 2015 Sushma 2015 Sushma 2015 Sushma 2015 Sushtal (25% CI)	805 1658 6.91, df= Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118 532 302 105 105 125 136 137 469 122 811 81 255 136 233 1105 78 467	1058 2219 3 (P = 0.) P = 0.08) 461 552 163 213 1389 226 27 226 27 355 470 159 226 43 380 230 318 943 380 230 318 957 141 1020 93 381 1212 212 219	826 1714 1714 1717 1407); P= ± 355 573 401 157 1486 0.00001) 001) 251 208 338 242 208 338 242 251 208 338 242 277 778 802 278 105 278 105 278 105 278 105 278 105 278 105 278 105 208 208 208 208 208 208 208 208	1035 2232 57% 477 697 480 213 1867 213 1867 7 = 979 309 353 353 353 353 353 353 353 353 353 298 656 630 230 320 230 230 2426 298 202 212 212 212 212 212 212 212 212 212	4.6% 10.0% 1.8% 2.2% 3.0% 8.2% 1.0% 8.2% 6 6 6 6 6 7 7 8.8% 0.9% 3.8% 0.9% 3.8% 0.9% 3.8% 0.3% 8.2% 0.3% 8.2% 0.3% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.86 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 0.67 [0.52, 0.86] 0.54 [0.23, 0.50] 0.46 [0.14, 0.98] 1.18 [0.90, 1.54] 1.92 [0.98, 3.75] 1.71 [0.77, 1.33] 0.88 [0.38, 1.99] 0.92 [0.68, 1.23] 1.38 [0.95, 2.01] 1.28 [0.99, 1.63] 0.95 [0.95, 0.97]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [#] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Heterogeneity: Chi [#] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 B.Zhou 2011 B.Zhou 2015 Dou 2010 Dug 2015 Dou 2010 Gu 2013 Hetshemi 2016 Hu 2013 Kshittj 2010 L 2015 N. Wang 2015 Sushma 2010 Gu 2014 Shen 2015 Sushma 2015 Sushma 2015 Sushma 2015 Sushma 2015 Total events Heterogeneity: Chi [#] =	805 1658 6.91, df= Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118 532 302 105 495 111 257 469 122 811 81 257 136 136 137 6350 177.85, df	1058 2219 3 (P = 0.0) 461 552 163 1389 2 3 (P < (0 2 266 3 55 2 3 (P < (0 2 266 3 55 4 70 2 266 3 55 4 70 2 266 3 55 4 70 2 0.001 2 0.001	826 1714 1714 365 573 401 157 1486 0.00001) 001) 2511 208 338 242 251 208 338 242 255 552 105 552 105 77 788 105 552 105 77 788 105 77 788 105 552 77 788 105 552 77 788 105 552 77 788 105 552 77 788 105 552 77 788 105 77 77 788 105 77 77 788 105 77 77 788 105 77 77 788 105 74 77 77 788 105 74 77 77 78 77 77 78 77 77 78 77 77	1035 2232 57% 477 697 480 213 1867 897 480 213 1867 897 805 805 805 805 805 805 805 805 805 805	4.6% 10.0% 2.2% 3.0% 8.2% 6 6 6 6 6 6 7.0% 2.0% 1.3% 8.2% 6 6 7.0% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 1.20 [0.78, 1.85] 0.67 [0.52, 0.86] 0.34 [0.23, 0.50] 0.44 [0.41, 0.98] 1.18 [0.90, 1.54] 1.19 [0.98, 3.75] 1.07 [0.87, 1.33] 0.88 [0.98, 1.99] 0.92 [0.68, 1.23] 1.88 [0.95, 2.01] 1.22 [0.98, 1.66] 0.52 [0.68, 0.97] 1.22 [0.98, 0.57] 1.22 [0.98, 0.57] 1.20 [0.81, 1.43]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Pang 2010 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Brajušković 2015 Chu 2012 Deng 2015 Dou 2010 Gu 2013 Hashemi 2016 Hu 2013 Kshitij 2010 Li 2015 Ni 2015 Ni 2015 P. Li 2014 Pavlakis 2013 Qu 2014 Rama 2010 Roshni 2014 Shen 2015 Zhang 2015 Sushma 2015 Zhang 2013 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect:	805 1658 6.91, df= Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118 532 302 105 495 111 257 469 122 811 81 257 136 136 137 6350 177.85, df	1058 2219 3 (P = 0.0) 461 552 163 213 1389 = 3 (P < 0.000 2266 3555 213 1389 = 3 (P < 0.000 2266 355 365 365 365 365 365 365 3	826 1714 1714 365 573 401 157 1486 0.00001) 001) 2511 251 208 338 242 253 208 338 242 255 552 105 552 105 552 105 77 788 105 552 77 788 105 552 77 788 105 552 77 788 105 552 77 788 105 552 77 788 105 552 77 788 105 552 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 77 788 105 552 77 788 105 77 77 788 105 74 77 788 77 77 788 77 77 788 77 77	1035 2232 57% 477 697 480 213 1867 7 = 979 309 353 353 353 353 353 353 365 298 656 0230 230 230 230 230 230 230 2426 2597 100 100 6597 100 213 297 80 297 80 202 202 202 202 202 202 202 202 202	4.6% 10.0% 1.8% 2.2% 3.0% 8.2% 6 6 6 6 6 6 6 6 7 1.0% 2.0% 1.0% 2.0% 2.0% 0.3% 3.8% 0.9% 3.8% 0.9% 3.8% 0.9% 3.9%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.36 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [101, 1.76] 1.34 [103, 2.68] 0.67 [0.42, 1.05] 1.34 [101, 1.76] 1.34 [0.95, 1.86] 1.20 [0.78, 1.85] 1.20 [0.78, 1.85] 1.70 [0.87, 1.33] 0.88 [0.98, 1.13] 1.88 [0.98, 1.66] 0.92 [0.68, 0.97] 0.22 [0.09, 0.57] 1.08 [0.81, 1.43] 0.90 [0.84, 0.97]	
Tian 2009 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: 3.1.5 Gastric Masaaki 2010 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Panagiotis 2014 Heterogeneity: Chi [™] = Test for overall effect: 3.1.6 Other Types B.Zhou 2011 Subtotal (95% CI) Total events Heterogeneity: Chi [™] = Lashemi 2016 Hu 2013 Kshitij 2010 Li 2015 N. Wang 2015 Sushma 2016 Roshni 2014 Rama 2010 Roshni 2014 Sushma 2015 Sushtal (95% CI) Total events Heterogeneity: Chi [™] = Test for overall effect: Total (95% CI)	805 1658 6.91, df= Z=1.77 (f 361 447 61 137 1006 93.72, df= Z=5.05 (f 180 80 413 118 532 302 105 495 111 257 495 111 257 495 136 136 233 1105 78 467 6350 177.85, df Z=2.95 (f	1058 2219 3 (P = 0.0) 461 552 163 1389 2 3 (P < (0 2 266 3 55 2 3 (P < (0 2 266 3 55 4 70 2 266 3 55 4 70 2 266 3 55 4 70 2 0.001 2 0.001	826 1714 1714 365 573 401 157 1486 0.00001) 001) 251 208 338 242 251 208 338 242 552 552 552 552 552 77 788 105 788 105 798 105 778 141 206 543 105 75 105 75 105 75 105 75 208 208 208 208 208 208 208 208	1035 2232 57% 477 697 480 213 1867 7 = 979 309 353 353 353 353 353 353 365 298 656 0230 230 230 230 230 230 230 2426 2597 100 100 6597 100 213 297 80 297 80 202 202 202 202 202 202 202 202 202	4.6% 10.0% 2.2% 3.0% 8.2% 6 6 6 6 6 6 7.0% 2.0% 1.3% 8.2% 6 6 7.0% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 2.2% 0.3% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.34 [1.01, 1.76] 1.33 [0.95, 1.86] 1.20 [0.78, 1.85] 0.67 [0.52, 0.86] 0.34 [0.23, 0.50] 0.44 [0.41, 0.98] 1.18 [0.90, 1.54] 1.19 [0.98, 3.75] 1.07 [0.87, 1.33] 0.88 [0.98, 1.99] 0.92 [0.68, 1.23] 1.88 [0.95, 2.01] 1.22 [0.98, 1.66] 0.62 [0.68, 0.97] 1.22 [0.98, 0.57] 1.22 [0.98, 0.57] 1.20 [0.81, 1.43]	
Fian 2009 Subtotal (95% CI) fotal events Heterogeneity: Chi≇ = Frest for overall effect: 3.1.5 Gastric Wan 2012 Masaaki 2010 Panagiotis 2014 Pang 2010 Subtotal (95% CI) fotal events Heterogeneity: Chi≇ = Fest for overall effect: 3.1.6 Other Types 3.2 hou 2011 Braijušković 2015 Chu 2012 Deng 2015 Dou 2010 Gu 2013 Hashemi 2016 Hu 2013 Chi 2015 Ni 2015 Pi Li 2014 Pavakaki 2013 Du 2015 Subtotal (95% CI) Total events Heterogeneity: Chi≇ = Fest for overall effect: Subtoral (95% CI) Total events Heterogeneity: Chi≇ = Fest for overall effect: Test for overall effect: Test for overall effect: Test for overall effect: Subtoral effect: Test for overall effect: Test for overal	805 1658 6.91, df=' Z = 1.77 (f 361 447 61 137 1006 93.72, df=' Z = 5.05 (f 180 80 413 118 2302 105 495 111 255 136 233 1105 78 467 6350 177.85, df Z = 2.95 (f 14886	1058 2219 3 (P = 0.0) 461 552 163 213 1389 2 3 (P = () P = 0.08) 461 552 163 213 1389 2 461 5 2 2 16 3 (P = () P = 0.08) 2 10 3 (P = 0, 0) 2 0 6 43 3 80 2 10 3 85 5 7 1 41 1 1020 3 81 9 3 8 597 1 441 1 1020 5 70 8 597 2 41 1 1020 5 70 8 597 2 41 1 1020 5 70 2 11 1 1020 5 70 5 70	826 1714 1714 355 573 401 157 1486 0.00001) 001) 2511 208 338 242 208 338 242 208 338 242 208 338 242 208 338 242 209 278 109 278 1486 552 169 177 1486 552 169 278 149 109 278 149 109 278 149 109 278 149 157 1486 552 149 109 278 149 109 278 149 109 278 149 149 149 149 149 149 149 149	1035 2232 57% 477 697 480 213 1867 213 1867 7 97 697 309 353 353 425 298 656 6380 230 320 320 230 320 230 230 2426 (597 426 259 26 690 1026 1026 1026 1026 1026 1026 1026 102	4.6% 10.0% 1.8% 2.2% 3.0% 8.2% 1.3% 8.2% 6 6 6 6 6 7 7 8.8% 1.0% 2.2% 0.3% 2.0% 2.2% 0.3% 2.2% 0.3% 39.3% 100.0%	0.81 [0.65, 0.99] 0.88 [0.77, 1.01] 1.24 [0.92, 1.68] 0.92 [0.69, 1.23] 0.12 [0.08, 0.18] 0.42 [0.42, 0.97] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 0.66 [0.56, 0.77] 1.36 [1.30, 2.68] 0.67 [0.42, 1.05] 1.34 [101, 1.76] 1.34 [103, 2.68] 0.67 [0.42, 1.05] 1.34 [101, 1.76] 1.34 [0.95, 1.86] 1.20 [0.78, 1.85] 1.20 [0.78, 1.85] 1.70 [0.87, 1.33] 0.88 [0.98, 1.13] 1.88 [0.98, 1.66] 0.92 [0.68, 0.97] 0.22 [0.09, 0.57] 1.08 [0.81, 1.43] 0.90 [0.84, 0.97]	

Figure 2: Forest plot of cancer risk in different cancer types associated with miR-196a2 rs11614913 polymorphism for recessive model (TT + TC vs. CC).

miR-499 A.G rs3746444

For miR-499A.G rs3746444, our mate-analysis included 37 studies (13759 cases and 17946 controls). our mate-analysis results are showed in Supplementary Table 2. On the whole, we found that miR-499A.G rs3746444 was significantly associated with decreased risks of cancers under the G vs. A (OR = 1.14, 95% CI = 1.09–1.19, $P_{\rm H} < 0.00001$), GG vs. AA (OR = 1.20, 95% CI = 1.08–3.11, $P_{\rm H} < 0.001$), AG vs. AA (OR = 1.20, 95% CI = 1.08–3.11, $P_{\rm H} < 0.0001$), GG + GA vs. AA (OR = 1.16, 95% CI = 1.08–1.25, $P_{\rm H} = 0.07$) and GG vs. AG + AA (OR = 1.20, 95% CI = 1.09–1.33, $P_{\rm H} < 0.00001$).

In stratified analysis according to cancer types, we investigated the significant associations with breast cancer were only maintained under the G vs. A (OR = 1.18, 95%CI = 1.09-1.27, $P_{H} = 0.04$), GG vs. AA (OR = 1.29, 95%) CI = 1.08 - 1.56, $P_{H} = 0.04$), GG + GA vs. AA (OR = 1.29, 95% CI = 1.08–1.54, $P_{H=}^{-1.54}$, $P_{H=}^{-1.54}$, and GG vs. AG + AA $(OR = 1.18, 95\% CI = 1.08 - 1.29, P_{H} = 0.18)$. However, no statistically significant association was found in colorectal, lung, liver or other types cancers (Figure 4). Subgroup analysis according to ethnicity, significant associations with increased risks of cancers were found in Asian population (OR = 1.13, 95% CI = 1.08–1.19, $P_{\rm H} < 0.00001$ for G vs. A; OR = 1.19, 95% CI = 1.06–1.34, $P_{H} = 0.006$ for GG vs. AA; OR = 1.17, 95% CI = 1.04–1.32, $P_{H=}0.01$ for GG + GA vs. AA; OR = 1.12, 95% CI = 1.06–1.19, P_{H} < 0.00001 for GG vs. AG + AA), and in Caucasian (OR = 1.16, 95% CI = 1.06–1.26, $P_{\rm H}$ < 0.00001 for G vs. A; OR = 1.29, 95% CI = 1.07–1.57, $P_{H} < 0.00001$ for GG + GA vs. AA; OR = 1.16, 95% CI = 1.04-1.29, P_H = 0.001 for GG vs. AG + AA) (Figure 5). According to study design, we found significant association between population-based studies with elevated risks of cancer (OR = 1.15, 95%CI = 1.10-1.20, $P_{H} < 0.00001$ for G vs. A; OR = 1.22, 95% CI = 1.09–1.36, P_H < 0.00001 for GG vs. AA; OR = 1.14, 95% CI = 1.08–1.20, P_H < 0.00001 for GG + GA vs. AA; OR = 1.14, 95% CI = 1.08–1.20, P_H < 0.00001 for GG vs. AG + AA), but the hospital-based studies was not observed a significant association summarized in Supplementary Table 2.

Sensitivity analysis

In the sensitivity analysis, each study involved in our meta-analysis was deleted the influence of the individual data on the coalescent ORs. The results of sensitivity analysis showed no obvious effects in overall population.

Publication bias

Begg's funnel plot and Egger's test were undertaken to evaluate the potential publication bias for this study. The shape of the Begg's funnel plots revealed no obvious asymmetry in all genotypes in overall population (Figures 6 and 7). The Egger's test did not reveal publication bias (P > 0.05).

DISCUSSION

The most common form of genetic sequence variation, SNPs are affecting miRNAs sequence coding, splicing and expression such as miRNA gene in human genome, which can affect the susceptibility of cancer including Asian and Caucasian [83]. It was detected in much previous research effort that the role of SNPs is located in miRNA sequence of miR-196a2 C.T (rs11614913) and miR-499 A.G (rs3746444) and influences on the progression of cancers [84]. Recently, several studies have investigated genetic variants of the miRNA SNPs in cancer susceptibility, but conclusions of those studies remain inconclusive. In this study, we conducted a meta-analysis to evaluated the association between the overall cancers susceptibility and the two polymorphisms in miRNA (miR-196a2 C.T rs11614913, miR-499 A.G rs3746444).

For miR-196a2 C.T rs11614913 polymorphism, although previous studies have revealed no association between cancer susceptibility and the expression of miR-196a2 rs11614913 [85-86]. Recently, the results of these meta-analysis studies have indicated a significant association between cancers susceptibility and miR-196a2 C.T rs11614913 [87-92]. The SNPs of miR-196a2 have caused increasing attention because they influence on the maturation progression and mutation of miRNA, and they play potential roles in tumor development and progression(cell proliferation, differentiation, apoptosis, migration and invasion). The predecessor found that the genetic sequence variation in miR-196a2 C.T rs11614913 is located in the 3' passenger (3p) mature sequence of miR-196a2, and this functional polymorphism is reportedly associated with the susceptibility of multiple kind of tumors (lung cancer and breast cancer). However, there was lower survival rates in small cell lung cancer, gliomas, gastric cancer, gallbladder, head and neck, esophageal, and HCC. During this interim of more than one year, some relevant case-control studies have been published, while conclusions of the relevant studies remain incomprehensive and inconsistent. For example, Dai et al. [32] results revealed that the miR-499 A.G rs3746444 polymorphisms are related to increased risks of breast cancer, while the miR-196a2 C.T rs11614913 polymorphisms are connected with reduced risks of breast cancer. Wei's studies [93] suggested that the miR-196a2 C.T rs11614913 might not be connected with susceptibility to gastric cancer, while our study revealed that the miR-196a2 C.T rs11614913 decrease risks to cancer, especially colorectal and gastric cancer in Asians population, and that the miR-499A.G rs3746444 may increase risks of cancer. In subgroup analysis by cancer

	Experim	nental	Cont	rol		Odds Ratio	Odds Ratio
Study or Subgroup	Events		Events		Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
38.1.1 Asian	004		0.55		4.70		L
Ahn 2012 Alshatwi 2012	361 98	461 100	355 96	477 100	1.7% 0.0%	1.24 [0.92, 1.68] 2.04 [0.37, 11.41]	
B.Zhou 2011	180	226	251	309	1.0%	0.90 [0.59, 1.39]	-
Bansal 2014	53	121	80	164	0.8%	0.82 [0.51, 1.31]	
Chu 2012	413	470	338	425	1.0%	1.86 [1.30, 2.68]	
Dai 2015	363	560	428	583	3.3%	0.67 [0.52, 0.86]	+
Deng 2015	118	159	242	298	1.0%	0.67 [0.42, 1.05]	
Dou 2010	532 302	643 380	513 283	656 380	1.9% 1.3%	1.34 [1.01, 1.76] 1.33 [0.95, 1.86]	
Gu 2013 H.Chen 2011	99	126	313	407	0.7%	1.10 [0.68, 1.79]	
H.Zhao 2016	83	114	86	114	0.5%	0.87 [0.48, 1.58]	
Hashemi 2016	105	169	105	182	0.8%	1.20 [0.78, 1.85]	+
Hong 2011	320	406	332	428	1.5%	1.08 [0.77, 1.50]	
Hu 2013	495	680	552	690	3.3%	0.67 [0.52, 0.86]	+
Kim1 2012	125	159	156	201	0.7%	1.06 [0.64, 1.75]	
Kim2 2010	467	654 271	485 407	640 532	3.1%	0.80 [0.62, 1.02]	
Kou 2014 Kshitij 2010	187 111	230	169	230	1.9% 1.9%	0.68 [0.49, 0.95] 0.34 [0.23, 0.50]	
Kuo 2014	147	188	267	377	0.9%	1.48 [0.98, 2.23]	
Li 2015	257	318	278	320	1.2%	0.64 [0.41, 0.98]	
Liu 2010	232	310	180	222	1.2%	0.69 [0.45, 1.06]	
Lv 2013	337	353	422	540	0.3%	5.89 [3.43, 10.12]	
M. Zhang 2011	237	252	226	248	0.3%	1.54 [0.78, 3.04]	
Masaaki 2010	447	552	573	697	2.1%	0.92 [0.69, 1.23]	
Min 2012	326	446	402	502	2.3%	0.68 [0.50, 0.91]	
N. Wang 2015 Ni 2015	469 122	597 141	452 77	597 100	2.1% 0.3%	1.18 [0.90, 1.54] 1.92 [0.98, 3.75]	
Omrani 2014	18	236	25	203	0.6%	0.59 [0.31, 1.11]	
P. Li 2014	811	1020	788	1006	3.6%	1.07 [0.87, 1.33]	+
P.Qi 2015	287	321	273	290	0.7%	0.53 [0.29, 0.96]	
Peng 2010	137	213	157	213	1.2%	0.64 [0.42, 0.97]	
Qi 2011	279	361	299	391	1.4%	1.05 [0.75, 1.47]	+
Qu 2014	255	381	293	426	2.0%	0.92 [0.68, 1.23]	T_
Rama 2010	136	212	141	250	1.0%	1.38 [0.95, 2.01]	
Roshni 2014 Shon 2015	233 1105	451 1400	206	452 2185	2.2%	1.28 [0.98, 1.66]	
Shen 2015 Tian 2009	805	1058	1793 826	1035	6.5% 4.4%	0.82 [0.69, 0.97] 0.81 [0.65, 0.99]	+
Yan 2015	228	274	301	328	1.0%	0.44 [0.27, 0.74]	
Z.Hu 2008	770	1009	875	1093	4.4%	0.80 [0.65, 0.99]	+
Zhang 2013	467	570	544	673	2.0%	1.08 [0.81, 1.43]	
Zhao 2013	215	235	158	281	0.3%	8.37 [5.00, 14.01]	
Zhou 2014	173	266	215	281	1.6%	0.57 [0.39, 0.83]	
Zhu 2011	140	573	121	588	2.0%	1.25 [0.95, 1.64]	F-
Subtotal (95% CI) Total events	13045	17666	15083	20114	72.2%	0.96 [0.92, 1.01]	1
Heterogeneity: Chi ² =		f = 42 (P		11): I ² = 8	4%		
Test for overall effect:							
20 4 2 Courseion							
38.1.2 Caucasian Behnaz 2016	75	103	306	432	0.7%	1.10 [0.68, 1.78]	+
Brajušković 2015	80	355	208	432	3.6%	0.20 [0.15, 0.28]	÷
Catucci 2012	1086	1894	1623	2760	12.5%	0.94 [0.84, 1.06]	
Dominik 2011	119	187	113	171	1.0%	0.90 [0.58, 1.39]	-+
Eman 2016	42	65	70	150	0.3%	2.09 [1.14, 3.81]	
Linhare 2012	294	388	261	388	1.4%	1.52 [1.11, 2.08]	_
Morales 2016	248	440	465	807	3.2%	0.95 [0.75, 1.20]	Т
P. Dikaiakos 2015 Papagiotis 2014	266 61	157 163	138 401	299 480	2.8%	Not estimable 0.12 [0.08, 0.18]	
Panagiotis 2014 Pavlakis 2013	81	93	108	480	0.3%	0.88 [0.38, 1.99]	
Renata 2012	115	197	125	212	1.1%	0.98 [0.66, 1.45]	-
Serena 2011	66	101	71	129	0.5%	1.54 [0.90, 2.64]	+
Sushma 2015	78	100	96	102	0.5%	0.22 [0.09, 0.57]	<u> </u>
Subtotal (95% CI)		4243		6405	27.8%	0.81 [0.74, 0.88]	•
Total events	2611		3985				
Heterogeneity: Chi ² = Test for overall effect:				J1); I² = 9	15%		
		21909	2010121	26510	100.0%	0.9210.99 0.061	
Total (95% CI) Total events	15656	Z 1909	19068	20319	100.0%	0.92 [0.88, 0.96]	1
Heterogeneity: Chi ² =		f = 54 (P)1): I ² = 9	39%		
Test for overall effect:		1					0.01 0.1 i 10 100
Test for subaroup diff				1 (P = 0	0004). P	= 92.0%	avours [experimental] Favours [control]

Figure 3: Forest plot of cancer risk in different ethnicity associated with miR-196a2 rs11614913 polymorphism for recessive model (TT+TC vs. CC).




Figure 4: Forest plot of cancer risk in different cancer types associated with miR-499 rs3746444 polymorphism for recessive model (GG+GA vs. AA).

type, ours results indicate that significant association with risks of cancer was observed in colorectal, gastric and lung cancer. But we did not detect significant association in breast cancer. While Christensen et al. [94] showed the miR-196a2C.T rs11614913 may reduced incidence of breast cancer. In subgroup analysis according to ethnicity, we found the significant association with risks of cancer in Asian population, indicating a possible role of differences in genetic backgrounds between Asians and Caucasians.

As for miR-499A.G rs3746444 polymorphism, the pooled results studies revealed that the miR-499A.G rs3746444 was association with risks of cancer in multiple

types of cancer [95–97]. Several studies showed that a large amount of miRNAs are abnormally expressed in various cancers, and Zhang et al. [98] found that approximately 50% miRNA genes are located in cancerassociated regions, so miRNAs possibly exert a signifcant effect on the tumorigenesis. It was reported that studies have shown that the miR-499 rs3746444 can regulate the expression of SOX genes. The over-expression of SOX6 could reverse the anti-apoptosis effects of miR-499 A.G rs3746444 [99]. The abnormal expression of SOX genes can activate Wnt/ β -catenin signaling pathway, which is associated with tumorigenesis and progression, so

Zhao 2013 24 Zhou 2014 23 Subtotal (95% Cl) 1 Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	Total Ex 461 100 226 121 969 470 184 560 159 380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400 1058 1058	vents 14 15 15 13 24 11 14 11 33 26 13 7 31 15 9 33 12 0 25 37 35 47	Total 477 100 309 164 363 425 184 583 380 182 690 452 201 532 230 377 697 502 100 203 290 250	Weightt 1.9% 2.0% 1.8% 1.7% 2.7% 0.4% 3.2% 1.5% 1.5% 1.6% 3.9% 3.6% 1.8% 0.9% 2.9% 2.0% 4.1% 1.6%	M-H, Fixed, 95% CI 1.11 [0.53, 2.33] 0.49 [0.20, 1.22] 0.72 [0.30, 1.73] 0.99 [0.44, 2.25] 0.71 [0.36, 1.41] 3.69 [1.03, 13.15] 0.68 [0.35, 1.31] 1.73 [0.81, 3.69] 0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.64, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	M-H, Fixed, 95% C1
Ahn 2012 15 Alshatwi 2012 8 B.Zhou 2011 8 Bansal 2014 11 Cheng 2015 25 Chu 2012 12 D. Li 2014 17 Dai 2015 18 Deng 2015 7 Gu 2013 7 Hashemi 2016 25 Hu 2013 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kub 2015 0 Masaaki 2010 25 Shentij 2010 21 Kuo 2014 12 Masaaki 2010 25 Shen 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Zhau 2014 22 Wang 2014 22 Wang 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P	100 226 121 969 470 184 560 159 380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400	15 15 13 24 11 14 13 26 13 7 31 15 9 33 12 0 25 37 35	100 309 164 363 425 184 583 298 380 182 690 452 201 532 230 377 697 502 100 203 290	2.0% 1.8% 1.7% 2.7% 0.4% 3.2% 1.5% 1.4% 1.6% 3.9% 3.6% 1.8% 2.9% 4.1% 1.6% 2.9% 4.7%	0.49 [0.20, 1.22] 0.72 [0.30, 1.73] 0.99 [0.44, 2.25] 0.71 [0.36, 1.41] 3.69 [1.03, 13, 15] 0.68 [0.35, 1, 31] 1.73 [0.81, 3.69] 0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Alshatwi 2012 8 B.Zhou 2011 8 Bansal 2014 11 Cheng 2015 25 Chu 2012 12 D. Li 2014 17 Dai 2015 18 Deng 2015 7 Gu 2013 7 Hashemi 2016 25 Hu 2013 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kus 2010 21 Kuo 2014 12 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wang 2014 22 Wang 2015 29 ZHu 2008 44 Zhao 2013 24 Wang 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overa	100 226 121 969 470 184 560 159 380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400	15 15 13 24 11 14 13 26 13 7 31 15 9 33 12 0 25 37 35	100 309 164 363 425 184 583 298 380 182 690 452 201 532 230 377 697 502 100 203 290	2.0% 1.8% 1.7% 2.7% 0.4% 3.2% 1.5% 1.4% 1.6% 3.9% 3.6% 1.8% 2.9% 4.1% 1.6% 2.9% 4.7%	0.49 [0.20, 1.22] 0.72 [0.30, 1.73] 0.99 [0.44, 2.25] 0.71 [0.36, 1.41] 3.69 [1.03, 13, 15] 0.68 [0.35, 1, 31] 1.73 [0.81, 3.69] 0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
B.Zhou 2011 8 Bansal 2014 11 Cheng 2015 25 Chu 2012 12 D. Li 2014 17 Dai 2015 18 Deng 2015 7 Gu 2013 7 Hashemi 2016 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kim1 2012 3 Kim1 2012 14 Masaaki 2010 25 Min 2012 14 Min 2015 0 Ormani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wang 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Braijušković 2015 18 Catucci 2012 84 Eman 2016 42	226 121 969 470 184 560 169 380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400	15 15 3 24 11 14 13 26 13 7 31 15 9 33 12 0 25 37 35	309 164 363 425 184 583 298 380 182 690 452 201 532 230 377 697 502 100 203 290	1.8% 1.7% 2.7% 0.4% 3.2% 1.6% 3.9% 3.6% 1.8% 0.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	0.72 [0.30, 1.73] 0.99 [0.44, 2.25] 0.71 [0.36, 1.41] 3.69 [1.03, 13, 15] 0.68 [0.35, 1.31] 1.73 [0.81, 3.69] 0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Bansal 2014 11 Cheng 2015 25 Chu 2012 12 D. Li 2014 17 Dai 2015 18 Deng 2015 7 Gu 2013 7 Hashemi 2016 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kshitij 2010 21 Kuo 2014 12 Kshitij 2010 21 Kuo 2014 12 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Zhou 2014 23 Subtotal (95% CI) 17 Total events 622 Heterogeneity: Chi ^a = 48.92, df = Test for	121 969 470 184 560 159 380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400	15 13 24 11 14 13 26 13 7 31 15 9 33 12 0 25 37 35	164 363 425 184 583 298 380 182 690 452 201 532 230 377 697 502 100 203 290	1.7% 2.7% 0.4% 3.2% 1.5% 1.4% 1.6% 3.9% 3.6% 1.8% 2.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	0.99 [0.44, 2.25] 0.71 [0.36, 1.41] 3.69 [1.03, 13.15] 0.68 [0.35, 1.31] 1.73 [0.81, 3.69] 0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Cheng 2015 25 Chu 2012 12 D. Li 2014 17 Dai 2015 18 Deng 2015 7 Gu 2013 7 Hashemi 2016 25 Hu 2013 25 J. Shi 2015 31 Kim1 2012 Kou 2014 12 Kshitij 2010 21 Kuo 2014 1 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Zihao 2013 24 Zhou 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 8	969 470 184 560 159 380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400	13 324 11 14 13 26 13 7 31 15 9 33 12 0 25 37 35	363 425 184 583 298 380 182 690 452 201 532 230 377 697 502 100 203 290	2.7% 0.4% 3.2% 1.5% 1.6% 3.9% 3.6% 1.8% 0.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	0.71 [0.36, 1.41] 3.69 [1.03, 13.15] 0.68 [0.35, 1.31] 1.73 [0.81, 3.69] 0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Chu 2012 12 D. Li 2014 17 Dai 2015 18 Deng 2015 7 Gu 2013 7 Hashemi 2016 25 Hu 2013 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kshitij 2010 21 Kuo 2014 1 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Zhou 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 <t< td=""><td>470 184 560 159 380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400</td><td>3 24 11 14 13 26 13 7 31 15 9 33 12 0 25 37 35</td><td>425 184 583 298 380 182 690 452 201 532 230 377 697 502 100 203 290</td><td>0.4% 3.2% 1.5% 1.6% 3.9% 3.6% 0.9% 2.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%</td><td>3.69 [1.03, 13,15] 0.68 [0.35, 1.31] 1.73 [0.81, 3.69] 0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]</td><td></td></t<>	470 184 560 159 380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400	3 24 11 14 13 26 13 7 31 15 9 33 12 0 25 37 35	425 184 583 298 380 182 690 452 201 532 230 377 697 502 100 203 290	0.4% 3.2% 1.5% 1.6% 3.9% 3.6% 0.9% 2.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	3.69 [1.03, 13,15] 0.68 [0.35, 1.31] 1.73 [0.81, 3.69] 0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
D. Li 2014 17 Dai 2015 18 Deng 2015 7 Gu 2013 7 Hashemi 2016 25 Ju 2013 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kshitij 2010 21 Kuo 2014 12 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Subtotal (95% CI) 11 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect Z = 2.61 (P 33.1.2 Caucasian Braj	184 560 159 380 680 448 159 271 230 188 552 446 141 236 321 212 1400	24 11 14 13 26 13 7 31 15 9 33 12 0 25 37 35	184 583 298 380 182 690 452 201 532 230 377 697 502 100 203 290	3.2% 1.5% 1.4% 3.9% 3.6% 2.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	0.68 [0.35, 1.31] 1.73 [0.81, 3.69] 0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Dai 2015 18 Deng 2015 7 Gu 2013 7 Hashemi 2016 25 Hu 2013 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kshitij 2010 21 Kuo 2014 1 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Wang 2014 23 Subtotal (95% CI) 10 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012<	560 159 380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400	11 14 11 33 26 13 7 31 15 9 33 12 0 25 37 35	583 298 380 182 690 452 201 532 230 377 697 502 100 203 290	1.5% 1.4% 1.6% 3.9% 3.6% 1.8% 0.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	1.73 [0.81, 3.69] 0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Deng 2015 7 Gu 2013 7 Hashemi 2016 25 Hu 2013 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kshitij 2010 21 Kuo 2014 1 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Ormrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wang 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	159 380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400	14 11 33 26 13 7 31 15 9 33 12 0 25 37 35	298 380 182 690 452 201 532 230 377 697 502 100 203 290	1.4% 1.6% 3.9% 3.6% 1.8% 0.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	0.93 [0.37, 2.36] 0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Gu 2013 7 Hashemi 2016 25 Hu 2013 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kshitij 2010 21 Kuo 2014 12 Kuo 2014 12 Kshitij 2010 21 Kuo 2014 1 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wang 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Zhou 2014 23 Subtotal (95% CI) 10 Total events 622 Heterogeneity: Chi ^a = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84	380 169 680 448 159 271 230 188 552 446 141 236 321 212 1400	11 33 26 13 7 31 15 9 33 12 0 25 37 35	380 182 690 452 201 532 230 377 697 502 100 203 290	1.6% 3.9% 3.6% 1.8% 0.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	0.63 [0.24, 1.64] 0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.56, 1.63] 1.32 [0.84, 2.08] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Hashemi 2016 25 Hu 2013 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kshitij 2010 21 Kshitij 2010 21 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Zhao 2013 24 Zhao 2013 24 Zhou 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	169 680 448 159 271 230 188 552 446 141 236 321 212 1400	33 26 13 7 31 15 9 33 12 0 25 37 35	182 690 452 201 532 230 377 697 502 100 203 290	3.9% 3.6% 1.8% 0.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	0.78 [0.44, 1.38] 0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Hu 2013 25 J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kshitij 2010 21 Kshitij 2010 25 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = 7 Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	680 448 159 271 230 188 552 446 141 236 321 212 1400	26 13 7 31 15 9 33 12 0 25 37 35	690 452 201 532 230 377 697 502 100 203 290	3.6% 1.8% 0.9% 2.9% 0.9% 4.1% 1.6% 2.9% 4.7%	0.97 [0.56, 1.71] 2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
J. Shi 2015 31 Kim1 2012 3 Kou 2014 12 Kshilij 2010 21 Kuo 2014 1 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	448 159 271 230 188 552 446 141 236 321 212 1400	13 7 31 15 9 33 12 0 25 37 35	452 201 532 230 377 697 502 100 203 290	1.8% 0.9% 2.9% 0.9% 4.1% 1.6% 2.9% 4.7%	2.51 [1.30, 4.86] 0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Kim1 2012 3 Kou 2014 12 Kshitij 2010 21 Kuo 2014 1 Masaaki 2010 25 Masaaki 2010 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Wang 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	159 271 230 188 552 446 141 236 321 212 1400	7 31 15 9 33 12 0 25 37 35	201 532 230 377 697 502 100 203 290	0.9% 2.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	0.53 [0.14, 2.09] 0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Kou 2014 12 Kshitij 2010 21 Kuo 2014 1 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z Hu 2008 44 Zhao 2013 24 Wu 2013 4 Yan 2015 29 Z Hu 2008 44 Zhao 2013 24 Wu 2013 4 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	271 230 188 552 446 141 236 321 212 1400	31 15 9 33 12 0 25 37 35	532 230 377 697 502 100 203 290	2.9% 2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	0.75 [0.38, 1.48] 1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Kshitij 2010 21 Kuo 2014 1 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Zhao 2013 24 Zhou 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	230 188 552 446 141 236 321 212 1400	15 9 33 12 0 25 37 35	230 377 697 502 100 203 290	2.0% 0.9% 4.1% 1.6% 2.9% 4.7%	1.44 [0.72, 2.87] 0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Kuo 2014 1 Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Zhao 2013 24 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ^a = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	188 552 446 141 236 321 212 1400	9 33 12 0 25 37 35	377 697 502 100 203 290	0.9% 4.1% 1.6% 2.9% 4.7%	0.22 [0.03, 1.74] 0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Masaaki 2010 25 Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	552 446 141 236 321 212 1400	33 12 0 25 37 35	697 502 100 203 290	4.1% 1.6% 2.9% 4.7%	0.95 [0.56, 1.63] 1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Min 2012 14 Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = 1 Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	446 141 236 321 212 1400	12 0 25 37 35	502 100 203 290	1.6% 2.9% 4.7%	1.32 [0.61, 2.89] Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Ni 2015 0 Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Shen 2015 29 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Subtotal (95% CI) 11 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	141 236 321 212 1400	0 25 37 35	100 203 290	2.9% 4.7%	Not estimable 2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
Omrani 2014 61 P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	236 321 212 1400	25 37 35	203 290	4.7%	2.48 [1.49, 4.13] 1.32 [0.84, 2.08]	
P.Qi 2015 52 Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	321 212 1400	37 35	290	4.7%	1.32 [0.84, 2.08]	
Rama 2010 25 Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	212 1400	35			1.32 [0.84, 2.08]	
Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Zhao 2013 24 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	1400		250	4.1%	문화 같은 것이 같은 것이 같은 것이 같은 것이 것이 없다.	
Shen 2015 29 Tian 2009 24 Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Zhou 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42		47			0.82 [0.47, 1.42]	
Wang 2014 22 Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Zhou 2014 23 Subtotal (95% Cl) 1 Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	1059		2185	5.2%	0.96 [0.60, 1.54]	
Wu 2013 4 Yan 2015 29 Z Hu 2008 44 Zhao 2013 24 Zhou 2014 23 Subtotal (95% Cl) 1 Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	1030	26	1035	3.7%	0.90 [0.51, 1.58]	
Wu 2013 4 Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Zhou 2014 23 Subtotal (95% Cl) 1 Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	152	24	304	2.0%	1.97 [1.07, 3.65]	
Yan 2015 29 Z.Hu 2008 44 Zhao 2013 24 Zhou 2014 23 Subtotal (95% CI) 1 Total events 622 Heterogeneity: Chi™ = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	200	3	211	0.4%	1.41 [0.31, 6.40]	<u> </u>
Z Hu 2008 44 Zhao 2013 24 Zhou 2014 23 Subtotal (95% Cl) 1 Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	274	28	328	3.3%	1.27 [0.73, 2.19]	
Zhao 2013 24 Zhou 2014 23 Subtotal (95% Cl) 1 Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	1009	29	1093	3.9%	1.67 [1.04, 2.69]	
Zhou 2014 23 Subtotal (95% Cl) 1 Total events 622 Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	235	16	281	1.9%	1.88 [0.98, 3.64]	
Subtotal (95% Cl) 1 Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	266	16	281	2.1%	1.57 [0.81, 3.04]	
Total events 622 Heterogeneity: Chi² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42	12277		13707	74.1%	1.17 [1.04, 1.32]	•
Heterogeneity: Chi ² = 48.92, df = Test for overall effect: Z = 2.61 (P 33.1.2 Caucasian Brajušković 2015 18 Catucci 2012 84 Eman 2016 42		600				
Brajušković 2015 18 Catucci 2012 84 Eman 2016 42			= 41%			
Catucci 2012 84 Eman 2016 42						
Eman 2016 42	355	22	353	3.0%	0.80 [0.42, 1.53]	
	1894	120	2760	13.6%	1.02 [0.77, 1.36]	+
Hikmet 2011 90	65	27	150	0.8%	8.32 [4.31, 16.05]	
	222	82	222	7.1%	1.16 [0.79, 1.71]	
Serena 2011 7	101	11	129	1.3%	0.80 [0.30, 2.14]	
Sushma 2015 6	100	0	102	0.1%	14.10 [0.78, 253.71]	
Subtotal (95% CI)	2737		3716	25.9%	1.29 [1.07, 1.57]	•
Total events 247		262				
Heterogeneity: Chi ² = 39.40, df = Test for overall effect: Z = 2.61 (P		00001);	l² = 87%	6		
Total (95% CI)			17423	100.0%	1.20 [1.09, 1.33]	•
Total events 869	15014	862				
Heterogeneity: Chi ² = 88.68, df =	15014		$ ^{2} = 61$	96	F	.01 0.1 1 10 100

Figure 5: Forest plot of cancer risk in different ethnicity associated with miR-499 rs3746444 polymorphism for recessive model (GG+GA vs. AA).




Figure 6: Funnel plot assessing evidence of publication bias (miR-196a2 rs11614913 (TT+TC vs. CC)).




Figure 7: Funnel plot assessing evidence of publication bias (miR-499 rs3746444 (GG+GA vs. AA)).

miR-499 A.G rs3746444 may play a decisive role in the occurring of cancer by altering SOX genes' expression level. Moreover, the mate-analysis results from 37 studies revealed that the miR-499 rs3746444 G allele was revealed as a risk factor for cancers, in particular, for breast cancer or for in the Asian, which consistent with Hu's results [100]. Therefore, The results illustrated that cancer types and district classification could cause different effects between miR-499 A.G rs3746444 polymorphism and risks of cancer.

To our knowledge, the source of the heterogeneity, including miR-196a2 C.T rs11614913 and miR-499A.G rs3746444, were mainly results from different ethnicity, different cancer types, different source of controls, different selection of subjects and sample size. Therefore, we evaluated the source of heterogeneity by cancer types, ethnicity, different selection of subjects and sample size. Nevertheless, our meta-analysis indeed exist some boundedness. Firstly, lack of relevant published data from the collected studies of potential gene-to-gene and gene-to-environment interactions, which may adjust risks of cancer. Secondly, potential heterogeneity was detected in some comparison, because they are unavoidable. Finally, publication bias existed in studies.

In conclusion, our meta-analysis indicated that the miR-196a2 C.T rs11614913 is significantly associated with a decreased risk of cancers, especially in the subgroup of colorectal, lung and gastric cancer, or Asians. Contrary to the above, the miR-499A.G rs3746444 most likely contributes to increased susceptibility of cancer in overall population, especially in breast cancer. Furthermore, more well-designed researches with large sample size are still necessary to elucidate the correlation between polymorphisms and different kinds of cancers risk.

ACKNOWLEDGMENTS

Wanjun Yan and Shuqun Zhang designed and wrote this article. Wanjun Yan and Shuqun Zhang screened out relevant articles and extracted data. Wanjun Yan, Xiaoyan Gao, and Shuqun Zhang analyzed data. Wanjun Yan and Shuqun Zhang revised this article.

CONFLICTS OF INTEREST

The authors have no conflicts of interest in this work.

GRANT SUPPORT

This study was supported by National Natural Science Foundation, People's Republic of China (No. 81274136) and Program for New Century Excellent Talents in University of China (No. NCET-110439).

REFERENCES

- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10–29.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86.
- Paul L, Niels VH, Pia KV, Anastasia MS, Jaakko K, Markku K, Eero P, Axel Skytthe MS, Kari H. Environmental and heritable factors in the causationof cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343:78–85.
- 4. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350–55.
- 5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281–97.
- 6. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5:522–31.
- 7. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007; 302:1–12.
- Saunders MA, Liang H, Li WH. Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA. 2007; 104:3300–05.
- Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis. 2008; 29:1306–11.
- Tian T, Shu Y, Chen J, Hu Z, Xu L, Jin G, Liang J, Liu P, Zhou X, Miao R, Ma H, Chen Y, Shen H. A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev. 2009; 18:1183–87.
- Min KT, Kim JW, Jeon YJ, Jang MJ, Chong SY, Oh D, Kim NK. Association of the miR-146aC>G, 149C>T, 196a2C>T, and 499A>G polymorphisms with colorectal cancer in the Korean population. Mol Carcinog. 2012; 51:E65–73.
- Li XD, Li ZG, Song XX, Liu CF. A variant in microRNA-196a2 is associated with susceptibility to hepatocellular carcinoma in Chinese patients with cirrhosis. Pathology. 2010; 42:669–73.
- Hu Z, Liang J, Wang Z, Tian T, Zhou X, Chen J, Miao R, Wang Y, Wang X, Shen H. Common genetic variants in premicroRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat. 2009; 30:79–84.
- Okubo M, Tahara T, Shibata T, Yamashita H, Nakamura M, Yoshioka D, Yonemura J, Ishizuka T, Arisawa T, Hirata I. Association between common genetic variants in premicroRNAs and gastric cancer risk in Japanese population. Helicobacter. 2010; 15:524–31.
- 15. Chu YH, Tzeng SL, Lin CW, Chien MH, Chen MK, Yang SF. Impacts of microRNA gene polymorphisms on the susceptibility of environmental factors leading to carcinogenesis in oral cancer. PLoS One. 2012; 7:e39777.

- Dou TH, Wu QH, Chen X, Ribas J, Ni XH, Tang C, Huang FP, Zhou LF, Lu DR. A polymorphism of microRNA196a genome regionwas associated with decreased risk of glioma in Chinese population. J Cancer Res Clin Oncol. 2010; 136:1853–59.
- George GP, Gangwar R, Mandal RK, Sankhwar SN, Mittal RD. Genetic variation in microRNA genes and prostate cancer risk in North Indian population. Mol Biol Rep. 2011; 38:1609–15.
- DerSimonian R, Kacker R. Random-effects model for metaanalysis of clinical trials: an update. Contemp Clin Trials. 2007; 28:105–14.
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22:719–48.
- 20. Tobias A. Assessing the influence of a single study in the metaanalysis estimate. Stata Technical Bulletin. 1999; 15–17.
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629–34.
- 22. Ahn DH, Rah HC, Choi YK. Association of the miR-146aC>G, miR-149T>C,miR-196a2T>C, and miR-499A>G Polymorphisms With Gastric Cancer Risk and Survival in the Korean Population. Mol Carcinog. 2013; 52:E39–51.
- 23. Ali AA, Gowhar S, Hasan TN, Naveed AS, Amal AA, Mohammed A, Abdulaziz AA. Differential Expression Profileand Genetic Variants of MicroRNAs Sequences in Breast Cancer Patients. PLoS One. 2012; 7:e30049.
- Zhou B, Wang K, Wang Y, Xi M, Zhang Z, Song Y, Zhang L. Common genetic polymorphisms in pre-microRNAs and risk of cervical squamous cell carcinoma. Mol Carcinog. 2011; 50:499–505.
- 25. Bansal C, Sharma KL, Misra S, Srivastava AN, Mittal B, Singh US. Common genetic variants in pre-microRNAs and risk ofbreast cancer in the North Indian population. Ecancermedicalscience. 2014; 8: 473.
- 26. Riazalhosseini B, Mohamed Z, Apalasamy YD, Eng HS, Mohamed R. Association between microRNA-196A2 and microRNA-146A polymorphisms and progression to cirrhosis and hepatocellular carcinoma in patients with viral hepatitis B. Pharmacogenet Genomics. 2016; 26:74–79.
- 27. Nikolić Z, Savić Pavićević D, Vučić N, Cidilko S, Filipović N, Cerović S, Vukotić V, Romac S, Brajušković G. Assessment of association between genetic variants in microRNA genes hsa-miR-499, hsa-miR-196a2 and hsamiR-27a and prostate cancer risk in Serbian population. Exp Mol Pathol. 2015; 99:145–50.
- Kim WH, Min KT, Jeon YJ, Kwon CI, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, Hwang SG, Kim NK. Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene. 2012; 504:92–97.
- 29. Cai M, Zhang Y, Ma Y, Li W, Min P, Qiu J, Xu W, Zhang M, Li M, Li L, Liu Y, Yang D, Zhang J, Cheng F. Association

between microRNA-499 polymorphism and gastric cancer risk in Chinese population. Bull Cancer. 2015; 102:973–78.

- Chu YH, Tzeng SL, Lin CW, Chien MH, Chen MK, Yang SF. Impacts of microRNA gene polymorphisms on the susceptibility of environmental factors leading to carcinogenesis in oral cancer. PLoS One. 2012; 7:e39777.
- Li D, Peng JJ, Tan Y, Chen T, Wei D, Du M, Zhang T. Genetic variations in microRNA genes and susceptibility to hepatocellular carcinoma. Genet Mol Res. 2015; 14:1926–31.
- 32. Dai ZM, Kang HF, Zhang WG, Li HB, Zhang SQ, Ma XB, Lin S, Wang M, Feng YJ, Liu K, Liu XH, Xu P, Dai J. The Associations of Single NucleotidePolymorphisms in miR196a2, miR-499, and miR-608 With Breast Cancer Susceptibility. Medicine. 2016; 95:e2826.
- Dominik J, Gabrovska PN, Stephen RW. Single NucleotidePolymorphism in hsa-mir-196a-2 and Breast Cancer Risk: A Case Control Study. Twin Res Hum Genet. 2014; 417-421.
- 34. Dou T, Wu Q, Chen X, Ribas J, Ni X, Tang C, Huang F, Zhou L, Lu D. A polymorphism of microRNA196a genome region was associated with decreased risk of glioma in Chinese population. J Cancer Res Clin Oncol. 2010; 136:1853–59.
- 35. Toraih EA, Fawz MS, Elgazzaz MG, Hussein MH, Shehata RH, Daoud HG. Combined Genotype Analyses of Precursor miRNA196a2 and 499a Variants with Hepatic and Renal Cancer Susceptibility a Preliminary Study. Asian Pac J Cancer Prev. 2016; 17:3369–75.
- 36. Wei J, Zheng L, Liu S, Yin J, Wang L, Wang X, Shi Y, Shao A, Tang W, Ding G, Liu C, Chen S, Gu H. MiR-196a2 rs11614913 T > C polymorphism and risk of esophageal cancer in a Chinese population. Hum Immunol. 2013; 74:1199–205.
- Chen H, Sun LY, Chen LL. A variant in microRNA-196a2 is not associated with susceptibility to and progression of colorectal cancer in Chinese. Intern Med J. 2011; 42: e115–19.
- Zhao H, Xu J, Zhao D, Geng M, Ge H, Fu L, Zhu Z. Somatic Mutation of the SNP rs11614913 and Its Association with Increased MIR 196A2 Expression in Breast Cancer. DNA Cell Biol. 2016; 35:81–87.
- Mohsen O, Mohammad H, Ebrahim EN, Seyed-Shahaboddin H, Mohammad AM, Farshid A, Mohsen T. Hsa-mir-499 rs3746444 gene polymorphism is associatedwith susceptibility to breast cancer in an Iranian population. Biomarkers Med. 2014; 8:259–67.
- 40. Akkiz H, Bayram S, Bekar A, Akgöllü E, Üsküdar O. Genetic variation in the microRNA-499 gene and hepatocellular carcinoma risk in a Turkish population: lack of any association in a case-control study. Asian Pac J Cancer Prev. 2011; 12:3107–12.
- 41. Deng S, Wang W, Li X, Zhang P. Common genetic polymorphisms in pre-microRNAs and risk of bladder cancer. World J Surg Oncol. 2015; 13:297.
- 42. Hu E, Wang D, Zhang X, Li J, Hu Y, Gong H, Liu E. Four common polymorphisms in microRNAs and the risk

of adult glioma in a Chinese case-control study. J Mol Neurosci. 2013; 51:933–40.

- 43. Shi J, Liu Y, Liu J, Zhou J. Hsa-miR-449a genetic variant is associated with risk of gastric cancer in a Chinese population. Int J Clin Exp Pathol. 2015; 8:13387–92.
- 44. Min KT, Kim JW, Jeon YJ, Jang MJ, Chong SY, Oh D, Kim NK. Association of the miR-146aC>G, 149C>T, 196a2C>T, and 499A>G polymorphisms with colorectal cancer in the Korean population. Mol Carcinog. 2012; 51:E65–73.
- 45. Hong YS, Kang HJ, Kwak JY, Park BL, You CH, Kim YM, Kim H. Association between microRNA196a2 rs11614913 genotypes and the risk of non-small cell lung cancer in Korean population. J Prev Med Public Health. 2011; 44:125–30.
- 46. Kou JT, Fan H, Han D, Li L, Li P, Zhu J, Ma J, Zhang ZH, He Q. Association between four common microRNA polymorphisms and the risk of hepatocellular carcinoma and HBV infection. Oncol Lett. 2014; 8:1255–60.
- 47. Srivastava K, Srivastava A, Mittal B. Common genetic variants in pre-microRNAs and risk of gallbladder cancer in North Indian population. J Hum Genet. 2010; 55:495–99.
- Chu YH, Hsieh MJ, Chiou HL, Liou YS, Yang CC, Yang SF, Kuo WH. MicroRNA gene polymorphisms and environmental factors increase patient susceptibility to hepatocellular carcinoma. PLoS One. 2014; 9:e89930.
- Li T, Niu L, Wu L, Gao X, Li M, Liu W, Yang L, Liu D. A functional polymorphism in microRNA-196a2 is associated with increased susceptibility to non-Hodgkin lymphoma. Tumour Biol. 2015; 36:3279–84.
- Linhares JJ, Azevedo M Jr, Siufi AA, de Carvalho CV, Wolgien MC, Noronha EC, Bonetti TC, da Silva ID. Evaluation of single nucleotide polymorphisms in microRNAs (hsa-miR-196a2 rs11614913 C/T) from Brazilian women with breast cancer. BMC Med Genet. 2012; 13:119.
- Li XD, Li ZG, Song XX, Liu CF. A variant in microRNA-196a2 is associated with susceptibility to hepatocellular carcinoma in Chinese patients with cirrhosis. Pathology. 2010; 42:669–73.
- 52. Lv M, Dong W, Li L, Zhang L, Su X, Wang L, Gao L, Zhang L. Association between genetic variants in premiRNA and colorectal cancer risk in a Chinese population. J Cancer Res Clin Oncol. 2013; 139:1405–10.
- 53. Zhang M, Jin M, Yu Y, Zhang S, Wu Y, Liu H, Chen B, Li Q, Ma X, Chen K. Associations of miRNA polymorphisms and female physiological characteristics with breast cancer risk in Chinese population. Eur J Cancer Care (Engl). 2012; 21:274–80.
- 54. Okubo M, Tahara T, Shibata T, Yamashita H, Nakamura M, Yoshioka D, Yonemura J, Ishizuka T, Arisawa T, Hirata I. Association between common genetic variants in premicroRNAs and gastric cancer risk in Japanese population. Helicobacter. 2010; 15:524–31.
- 55. Kim MJ, Yoo SS, Choi YY, Park JY. A functional polymorphism in the pre-microRNA-196a2 and the risk of

lung cancer in a Korean population. Lung Cancer. 2010; 69:127–29.

- 56. Morales S, Gulppi F, Gonzalez-Hormazabal P, Fernandez-Ramires R, Bravo T, Reyes JM, Gomez F, Waugh E, Jara L. Association of single nucleotide polymorphisms in PremiR-27a, Pre-miR-196a2, Pre-miR-423, miR-608 and Pre-miR-618 with breast cancer susceptibility in a South American population. BMC Genet. 2016; 17:109.
- 57. Wang N, Li Y, Zhou RM, Wang GY, Wang CM, Chen ZF, Liu W. Hsa-miR-196a2 functional SNP is associated with the risk of ESCC in individuals under 60 years old. Biomarkers. 2014; 19:43–48.
- 58. Liu X, Xu B, Li S, Zhang B, Mao P, Qian B, Guo L, Ni P. Association of SNPs in miR-146a, miR-196a2, and miR-499 with the risk of endometrial/ovarian cancer. Acta Biochim Biophys Sin (Shanghai). 2015; 47:564–66.
- Mohsen O, Mohammad H, Ebrahim EN, Seyed-Shahaboddin H, Mohammad Ali M, Farshid A, Mohsen T. Hsa-mir-499 rs3746444 genepolymorphism is associatedwith susceptibility to breast cancer in an Iranian population. Biomarkers Med. 2014; 8:259–67.
- 60. Dikaiakos P, Gazouli M, Rizos S, Zografos G, Theodoropoulos GE. Evaluation of genetic variants in miRNAs in patients with colorectal cancer. Cancer Biomark. 2015; 15:157–62.
- 61. Li P, Yan H, Zhang H, Yu L, Wang Z, Zhai Y, Xia X, Zhang J, Zhang Y, Ma F, Huang W, Cai M, Cui Y, et al. A functional polymorphism in MIR196A2 is associated with risk and progression of nasopharyngeal carcinoma in the Chinese population. Genet Test Mol Biomarkers. 2014; 18:149–55.
- 62. Qi P, Wang L, Zhou B, Yao WJ, Xu S, Zhou Y, Xie ZB. Associations of miRNA polymorphisms and expression levels with breast cancer risk in the Chinese population. Genet Mol Res. 2015; 14:6289–96.
- Dikeakos P, Theodoropoulos G, Rizos S, Tzanakis N, Zografos G, Gazouli M. Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population. Mol Biol Rep. 2014; 41:1075–80.
- Pavlakis E, Papaconstantinou I, Gazouli M, Theodosopoulos T, Karamanolis G, Genatas K, Ladas SD. MicroRNA gene polymorphismsin pancreatic cancer. Pancreatology. 2013; 13: 273e278.
- 65. Qi P, Dou TH, Geng L, Zhou FG, Gu X, Wang H, Gao CF. Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum Immunol. 2010; 71:621–26.
- Peng S, Kuang Z, Sheng C, Zhang Y, Xu H, Cheng Q. Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig Dis Sci. 2010; 55:2288–93.
- 67. Qu Y, Qu H, Luo M, Wang P, Song C, Wang K, Zhang J, Dai L. MicroRNAs related polymorphisms and genetic

susceptibility to esophageal squamous cell carcinoma. Mol Genet Genomics. 2014; 289:1123–30.

- Rama DM, Ruchika G, George GP, Tulika M, Rakesh K. Investigative Role of Pre-MicroRNAs in Bladder Cancer Patients: A Case–Control Study in North India. DNA Cell Biol. 2011; 30:401–06.
- Hezova R, Kovarikova A, Bienertova-Vasku J, Sachlova M, Redova M, Vasku A, Svoboda M, Radova L, Kiss I, Vyzula R, Slaby O. Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol. 2012; 18:2827–31.
- 70. Roy R, De Sarkar N, Ghose S, Paul RR, Pal M, Bhattacharya C, Chowdhury SK, Ghosh S, Roy B. Genetic variations at microRNA and processing genes and risk of oral cancer. Tumour Biol. 2014; 35:3409–14.
- Vinci S, Gelmini S, Pratesi N, Conti S, Malentacchi F, Simi L, Pazzagli M, Orlando C. Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chem Lab Med. 2011; 49:2073–80.
- 72. Shen F, Chen J, Guo S, Zhou Y, Zheng Y, Yang Y, Zhang J, Wang X, Wang C, Zhao D, Wang M, Zhu M, Fan L, et al. Genetic variants in miR-196a2 and miR-499 are associated with susceptibility to esophageal squamous cell carcinoma in Chinese Han population. Tumour Biol. 2016; 37:4777–84.
- 73. Sushma PS, Jamil K, Kumar PU, Satyanarayana U, Ramakrishna M, Triveni B. Genetic Variation in MicroRNAs and Risk of Oral Squamous Cell Carcinoma in South Indian Population. Asian Pac J Cancer Prev. 2015; 16:7589–94.
- 74. Tian T, Shu Y, Chen J, Hu Z, Xu L, Jin G, Liang J, Liu P, Zhou X, Miao R, Ma H, Chen Y, Shen H. A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev. 2009; 18:1183–87.
- Wang XH, Wang FR, Tang YF, Zou HZ, Zhao YQ. Association of miR-149C>T and miR-499A>G polymorphisms with the risk of hepatocellular carcinoma in the Chinese population. Genet Mol Res. 2014; 13:5048–54.
- Wu XJ, Mi YY, Yang H, Hu AK, Li C, Li XD, Zhang QG. Association of the hsa-mir-499 (rs3746444) polymorphisms with gastric cancer risk in the Chinese population. Onkologie. 2013; 36:573–76.
- Yan P, Xia M, Gao F, Tang G, Zeng H, Yang S, Zhou H, Ding D, Gong L. Predictive role of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) in the development of hepatocellular carcinoma. Int J Clin Exp Pathol. 2015; 8:15177–83.
- 78. Hu Z, Liang J, Wang Z, Tian T, Zhou X, Chen J, Miao R, Wang Y, Wang X, Shen H. Common genetic variants in premicroRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat. 2009; 30:79–84.
- 79. Tong N, Xu B, Shi D, Du M, Li X, Sheng X, Wang M, Chu H, Fang Y, Li J, Wu D, Zhang Z. Hsa-miR-196a2

polymorphism increases the risk of acute lymphoblastic leukemia in Chinese children. Mutat Res. 2014; 759:16–21.

- Hao YX, Wang JP, Zhao LF. Associations between three common MicroRNA polymorphisms and hepatocellular carcinoma risk in Chinese. Asian Pac J Cancer Prev. 2014; 14:6601–04.
- Zhou B, Dong LP, Jing XY, Li JS, Yang SJ, Wang JP, Zhao LF. Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population. Tumour Biol. 2014; 35:7775–80.
- Zhu L, Chu H, Gu D, Ma L, Shi D, Zhong D, Tong N, Zhang Z, Wang M. A functional polymorphism in miRNA-196a2 is associated with colorectal cancer risk in a Chinese population. DNA Cell Biol. 2012; 31:350–54.
- Liu F, Li B, Wei Y, Chen X, Ma Y, Yan L, Wen T. P21 codon 31 polymorphism associated with cancer among white people: evidence from a meta-analysis involving 78,074 subjects. Mutagenesis. 2011; 26:513–21.
- Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010; 10:389–402.
- 85. Christensen BC, Avissar-Whiting M, Ouellet LG, Butler RA, Nelson HH, McClean MD, Marsit CJ, Kelsey KT. Mature microRNAsequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer. Clin Cancer Res. 2010; 16:3713–20.
- Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res. 2009; 69:5970–77.
- Xu W, Xu JI, Liu SF, Chen B, Wang XL, Li Y, Qian Y, Zhao WH, Wu JQ. Effects of common polymorphisms rs11614913 inmiR-196a2 and rs2910164 in miR-146a on cancer susceptibility: a meta-analysis. PLoS One. 2011; 6:e2047121.
- Chu HY, Wang ML, Shi DN, Ma L, Zhang ZZ, Tong N, Huo XY, Wang W, Luo DW, Gao Y, Zhang ZD. Hsa-miR-196a2 Rs11614913 polymorphismcontributes to cancer susceptibility: evidence from 15 case-control studies. PLOS One. 2011; 6:e18108.92.
- Wang F, Ma YL, Zhang P, Yang JJ, Chen HQ, Liu ZH, Peng JY, Zhou YK, Qin HL. A genetic variant in microRNA-196a2 is associated with increased cancer risk: a meta-analysis. Mol Biol Rep. 2012; 39:269–75.
- 90. He BS, Pan YQ, Cho WC, Xu YQ, Gu L, Nie ZL, Chen LP, Song GQ, Gao TY, Li R, Wang SK. The Association between Four Genetic Variants inMicroRNAs (rs11614913, rs2910164, rs3746444, rs2292832) and Cancer Risk: Evidence fromPublished Studies. PLOS ONE. 2012; 7: e49032.113.
- Wang J, Wang Q, Liu H, Shao N, Tan B, Zhang G, Wang K, Jia Y, Ma W, Wang N, Cheng Y. The association of miR-146a rs2910164 and miR-196a2 rs11614913

polymorphisms with cancer risk: a meta-analysis of 32 studies. Mutagenesis. 2012; 27:779–88.

- 92. Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One. 2012; 7:e50966.
- Wei Y, Li L, Gao J. The association between two common polymorphisms (miR-146a rs2910164 and miR-196a2 rs11614913) and susceptibility to gastric cancer: A metaanalysis. Cancer Biomark. 2015; 15:235–48.
- 94. Xu W, Xu J, Liu S, Chen B, Wang X, Li Y, Qian Y, Zhao W, Wu J. Effects of common polymorphisms rs11614913 in miR-196a2 and rs2910164 in miR-146a on cancer susceptibility: a meta-analysis. PLoS One. 2011; 6:e20471.
- 95. Min KT, Kim JW, Jeon YJ, Jang MJ, Chong SY, Oh D, Kim NK. Association of the miR-146aC>G, 149C>T, 196a2C>T, and 499A>G polymorphisms with colorectal cancer in the Korean population. Mol Carcinog. 2012; 51:E65–73.
- 96. Wang P, Xie S, Cui A, Zhang Y, Jiang B. miR-196a2 polymorphisms and susceptibility to cancer: A meta-

analysis involving 24,697 subjects. Exp Ther Med. 2012; 3:324–30.

- 97. Xiang Y, Fan S, Cao J, Huang S, Zhang LP. Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population. Mol Biol Rep. 2012; 39:7019–23.
- Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007; 302:1–12.
- 99. Li X, Wang J, Jia Z, Cui Q, Zhang C, Wang W, Chen P, Ma K, Zhou C. MiR-499 regulates cell proliferation and apoptosis during late-stage cardiac differentiation via Sox6 and cyclin D1. PLoS One. 2013; 8:e74504.
- 100. Hu Z, Liang J, Wang Z, Tian T, Zhou X, Chen J, Miao R, Wang Y, Wang X, Shen H. Common genetic variants in premicroRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat. 2009; 30:79–84.